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VI  FOREWORD 
Summary of the thesis 
In the field of drug discovery protein kinases have emerged as extremely promising 
therapeutic targets, as witnessed by the increasing amount of FDA-approved kinase 
inhibitors in the last decade. In particular, this thesis focuses on the c-Jun N-terminal 
kinases (JNKs), a group of enzymes belonging to the family of mitogen-activated protein 
kinases (MAPKs) which regulate the cell response to a variety of extracellular stress stimuli. 
The dysregulated activity of JNKs has been connected to diverse pathological states ranging 
from neurodegenerative disorders to cancer and inflammatory or metabolic diseases. 
However, despite the intense endeavor devoted to the research of novel inhibitors, no 
clinical candidate has reached approval in therapy to date. For this reason, the presented 
work pursued the targeting of JNKs by means of diverse strategies such as alternative 
biological assay methodologies and synthesis of small-molecule inhibitors.  
In the first part of the thesis a fluorescence polarization (FP)-based competition binding 
assay was developed as a tool to efficiently evaluate the affinity of novel inhibitors for the 
different JNK isoforms (JNK1, 2, and 3), as well as for the closely-related p38α MAPK. Such 
assay required the synthesis of a fluorescently-labeled probe based on a pyridinylimidazole 
scaffold which displayed Kd values in the low nM range for all the target enzymes. After 
optimizing the procedure conditions, the new FP assay was validated by employing known 
inhibitors and comparing the measured affinities with results from different methods. 
Finally, the suitability for the high throughput screening format was confirmed, 
highlighting the developed FP assay as a fast and relatively inexpensive methodology for 
the rapid screening of novel inhibitors.  
The second part of this thesis work consisted instead in the optimization of a dual 
JNK3/p38α MAPK pyridinylimidazole-based lead compound aimed at shifting the 
selectivity towards the JNK3. In detail, the substitution at different key positions of the 
scaffold, as well as the nature of the five-membered core were alternatively modified. 
Among the different attempts, the presence of a simple methyl group at the imidazole-C4 
position, together with a 2-methylsulfanyl moiety permitted to abolish the activity on the 
p38α MAPK while maintaining the inhibition on the JNK3. The best inhibitor of the series 
inhibited the JNK3 in the low triple digit nanomolar range, with a > 27-fold selectivity over 
the p38α MAPK. The achieved information concerning the structure-activity relationship 
(SAR) together with the crystal structure determination of the best inhibitor in complex 
with the JNK3 might aid the design of future optimization strategies.  
 
 
FOREWORD  VII 
Zusammenfassung der Dissertation 
Auf dem Gebiet der Wirkstoffforschung wurden Proteinkinasen als sehr vielversprechende 
therapeutische Ziele identifiziert.  Dies lässt sich insbesondere an der stetig steigenden 
anzahl an von der FDA zugelassenen Kinaseinhibitoren in den letzten fünfzehn Jahren 
erkennen. Die vorliegende Arbeit konzentriert sich im Speziellen auf c-Jun N-terminale 
Kinasen (JNKs), eine Gruppe von Enzymen aus der Familie der mitogenaktivierten 
Proteinkinasen (MAPKs), die die Zellantwort auf eine ganze Reihe extrazellulärer 
Stressreize regulieren. Störungen der Aktivität der JNKs wird mit zahlreichen Krankheiten 
wie neurodegenerativen Prozessen, Krebserkrankungen, Entzündungen oder 
Stoffwechselstörungen in Verbindung gebracht. Trotz intensiver Forschung an neuartigen 
Inhibitoren wurde bis heute aber kein Wirkstoff zugelassen. Die vorliegende Arbeit 
verfolgt daher das Ziel, die JNKs zum einen mittels alternativer biologischer Assays zu 
charakterisieren und zum anderen mittels der Synthese geeigneter Moleküle zu inhibieren. 
Der erste Teil der Arbeit behandelt die Entwicklung eines kompetitiven Bindungsassays 
auf Basis der Fluoreszenzpolarisationsmessung. Er dient als Werkzeug zur Bestimmung 
der Affinität der neuartigen Inhibitoren zu den drei verschiedenen Isoformen von JNK 
(JNK1, 2 und 3) sowie der damit engverwandten p38α MAPK. Der Assay erforderte die 
Synthese einer fluoreszenzmarkierten Verbindung auf Basis eines 
Pyridinylimidazolgerüstes, welche Kd-Werte im niedrigen nanomolaren Bereich für alle 
Zielenzyme aufweist. Nach der Optimierung der Bedingungen wurde der neue FP-Assay 
validiert, indem bekannte Inhibitoren getestet wurden und deren gemessene Affinitäten 
mit Ergebnissen aus anderen Methoden verglichen wurden. Schließlich wurde die Eignung 
des Assays zum schnellen und relativ kostengünstigen Hochdurchsatzscreening zur 
Identifizierung von neuartigen Inhibitoren bestätigt.  
Der zweite Teil der Arbeit befasst sich mit der Optimierung einer pyridinylimidazol-
basierten Testverbindung zur Hemmung von JNK3 und p38α MAPK mit dem Ziel die 
Selektivität hin zu JNK3 zu verschieben. Dazu wurden sowohl der zentrale Fünfring als 
auch die Substituenten variiert. So konnte gezeigt werden, dass eine einfache 
Methylgruppe an der Imidazol-C4-Position in Verbindung mit einer 2-
Methylsulfanylgruppe die Inhibition der p38α MAPK unterbindet während die JNK3 
weiterhin gehemmt wird. Die beste Verbindung dieser Serie inhibierte die JNK3 im 
niedrigen dreistelligen nanomolaren Bereich bei einer mehr als 27-fachen Selektivität 
gegenüber p38α MAPK.  
Die im Rahmen dieser Arbeit gewonnen Erkenntnisse hinsichtlich der Struktur-Wirkungs-
Beziehung (SAR), in Verbindung mit der erlangen Kristallstruktur des besten gefundenen 
JNK3-Inhibitors bilden die Grundlage für weitere Optimisierungsansätze in der Zukunft.
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1.  Introduction 
 
1.1.  Protein Kinases 
The family of protein kinases is constituted by enzymes catalyzing the reaction of 
phosphorylation, namely the covalent transfer of the γ-phosphate group from a nucleoside 
triphosphate (generally adenosine triphosphate (ATP)) to the free hydroxyl group of an 
amino acid side chain (Ser, Thr, and Tyr).1-3 In detail, depending on the targeted amino acid, 
these enzymes can be divided into Ser/Thr kinases, Tyr kinases, and dual-specificity 
Ser/Thr/Tyr kinases.2 The action of protein kinases is counterbalanced by corresponding 
protein phosphatases, which are able to reverse the process by cleaving the phosphoester 
bond.4 
Phosphorylation represents the most widespread and well-studied post-translational 
modification in eukaryotic organisms,5,6 with an estimation of more than 200,000 
phosphorylation sites within the human proteome.7 Kinases are able to recognize one or 
more substrates in an exceptionally specific fashion based both on local features, such as a 
determined consensus sequence surrounding the phosphorylation site, as well as spatially-
separated docking motifs, favoring the recruitment and the right positioning of the 
targets.8,9 Additionally, some kinases can associate with adaptors known as scaffold 
proteins forming supramolecular complexes which ease the identification and 
phosphorylation of the desired substrate.8,10 The introduction of a negatively-charged 
phosphoryl group produces a conformational modification of the targeted protein which 
can affect its functionality in a multitude of ways, like modulating its activation state, 
altering the interaction with molecular partners, and influencing its stability or cellular 
localization.11  
Protein kinases are among the major actors in signal transduction pathways, wherein 
various phosphorylation events represent key steps of signaling cascades which regulate 
nearly every basic cellular activity including proliferation, differentiation, apoptosis, 
immunity, and metabolism.11-14 The potential of different kinases to phosphorylate multiple 
sites on the same target15 as well as the coordinated activity of protein kinases and 
phosphatases4 allow the fine tuning of this biochemical process, thus confirming its pivotal 
role in the regulation of biological events. As a direct consequence, however, dysregulation 
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in the activity of protein kinases is strongly connected with several pathological states, 
causing these enzymes to emerge as potential drug targets in different therapeutic 
approaches.16,17 
Sequence alignment of eukaryotic protein kinases has allowed the detection of conserved 
features within their catalytic domains.18 Subsequent advancements in the human genome 
sequencing have then permitted to progressively broaden the number of genes belonging 
to this superfamily and to deduce their phylogeny.18-22 To date 518 genes have been 
included in the superfamily of protein kinases, accounting for approximately the 1.7% of 
the whole human genome and therefore acquiring the common denomination of “kinome”. 
The possibility of alternative splicing leads to an estimation of more than 1,000 members, 
making kinases one of the widest protein families in the human organism.21 Based on their 
sequence similarity and evolutionary relationships, human protein kinases have been 
classified into seven different groups as depicted in Figure 1.1: 
 
 AGC group: mainly contains kinases activated by second messengers like PKA, 
PKG, and PKC 
 CAMK group: includes kinases dependent on the Ca2+/calmodulin system 
 CMGC group: contains different classes of kinases generally activated by 
phosphorylation like cyclin-dependent kinases (CDKs) and 
mitogen-activated protein kinases (MAPKs) 
 TK group: composed of Tyr specific kinases often representing intracellular 
catalytic domains of membrane receptors 
 TKL group: a heterogeneous group including diverse kinases structurally 
related to Tyr kinases 
 STE group: includes upstream activators of MAPKs 
 CK1 group: mostly constituted by the casein kinase 1 family 
 
In addition, this classification includes a group of 40 atypical protein kinases exhibiting 
biochemical activity although lacking sequence similarity with the conserved kinase 
domain.   
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Figure 1.1 Representation of the human kinome phylogenetic tree as described by Manning et al.21 
The figure was obtained through the web-based tool KinMap;23 illustration reproduced courtesy of 
Cell Signaling Technology, Inc. (www.cellsignal.com).  
 
1.1.1.  Structure of protein kinases 
As previously mentioned, comparison of primary sequences of several kinase catalytic 
domains has led to the identification of conserved features, which have been therefore 
considered fundamental for the phosphotransfer activity. In particular, 12 conserved 
subdomains have been detected, separated by amino acid stretches which instead diverge 
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between the different classes of protein kinases.22 These identified subdomains mainly 
consist of sequences possessing a defined secondary structure and are involved in the 
formation of the active site and in the catalytic activity.4,18  
The high primary structure similarity reflects on a common folding shared by the majority 
of kinases. The catalytic domain of protein kinases, typically constituted by 250-300 amino 
acids, is characterized by a two-lobed structure comprising a small N-terminal lobe and a 
larger C-terminal domain, tethered by a flexible loop termed “hinge region”. The ATP is 
accommodated in a cleft at the interface between the two lobes, where the adenine group 
forms a bidentate hydrogen bond with the hinge region (Figure 1.2).2,3,24  
The N-terminal lobe, or N-lobe, is composed by a five-stranded antiparallel β-sheet motif 
and generally a single α-helix (the αC-helix) which represents an important regulatory 
element for the catalytic activity.24 A Lys residue in the N-lobe, belonging to a highly 
conserved motif Ala-Xxx-Lys, coordinates the α and β phosphate groups of ATP, and 
interacts with an almost invariable Glu residue of the αC-helix through the formation of a 
salt bridge, assumed to be crucial for the kinase activity. The flexible loop connecting β1 
and β2 strands, known as the Gly-rich loop, comprises a conserved motif Gly-Xxx-Gly-Xxx-
Xxx-Gly which coordinates the β and γ phosphates and was described to fold as a lid over 
the bound ATP in the kinase active form.3,22,24-27 
Oppositely to the N-lobe, the C-terminal domain is prevalently composed of α-helices and 
additionally contains four β-sheet strands (β6-β9). The latter constitute the bottom of the 
nucleotide binding cleft and comprise residues which are essential  for the catalytic 
activity.3,24 The catalytic loop, connecting β6 and β7 strands, contains most of the kinase 
catalytic machinery including the conserved motif His/Tyr-Arg-Asp (HRD/YRD motif). 
The Asp residue of this tripeptide takes part in the catalytic mechanism by extracting a 
proton from the hydroxyl group of the substrate while a nearly invariable Asn within the 
same loop binds a Mg2+ ion that interacts with the α and γ phosphates.24,28,29 Of primary 
importance for the regulation of the kinase catalytic activity is the activation loop, or A-
loop, which consists of a segment in the C-lobe whose length and composition vary 
depending on the kinase. This sequence typically comprises one or more phosphorylation 
sites which allow the activation of the enzyme by upstream kinases.29,30 The N-terminal end 
of the A-loop, often named Mg binding loop, contains the highly conserved Asp-Phe-Gly 
(DFG) motif in which the Asp residue points toward the ATP binding pocket and chelates 
a second Mg2+ ion coordinating the β and γ phosphate groups. The Phe side chain of the 
DFG tripeptide makes hydrophobic interactions with two residues of the αC-helix (N-lobe) 
and contributes to its correct positioning.27,30 
Analysis of the protein kinase folding also resulted in the identification of hydrophobic 
spines, namely series of non-continuous amino acid residues which are aligned and 
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interconnected in the kinase active form, thus forming skeletons that stabilize the two lobes. 
Although these structures are present in all kinases, the amino acid residues constituting 
them are not always conserved and are not detectable in primary structure. The regulatory 
spine, or R-spine, is composed of four residues, two in the N-lobe (of which one in the αC-
helix), and two in the C-lobe (the His/Tyr of the HRD/YRD motif in the catalytic loop and 
the Phe of the DFG motif). The catalytic spine is instead consisting of eight non-conserved 
hydrophobic residues belonging to both lobes and is completed by the adenine ring of the 
bound ATP.31,32 Both spines are anchored to the αF-helix, an extended α-helix sequence in 
core of the C-lobe.33 
Phosphorylation at one or multiple sites on the A-loop generally stabilizes the kinase in the 
active conformation. In this state, the DFG motif is described to be in an “in” conformation 
where the Asp points towards the ATP binding site and the Phe interacts with hydrophobic 
residues of the αC-helix. The αC-helix also assumes an “in” conformation and is rotated 
toward the catalytic site where the conserved Glu residue forms the aforementioned salt 
bridge with the Lys side chain of the Ala-Xxx-Lys sequence. In addition, both the R-spine 
and the catalytic spine are assembled.27-29,34 Conversely, inactive, non-phosphorylated 
kinases tend to adopt a “DFG-out” conformation where the positions of Asp and Phe 
residues are switched due to a flip of the tripeptide of about 180°. As a result, the Asp side 
chain points away from the ATP binding site, no longer stabilizing the phosphate groups 
through the Mg2+ ion. At the same time, the bulky side chain of Phe is shifted away from 
the αC-helix and faces the ATP pocket, in some cases sterically blocking the binding of the 
nucleotide. The inactive conformation is also characterized by a torsional movement of the 
αC-helix away from the binding site, preventing the formation of the catalytic salt bridge. 
The change of position of both αC-helix and the DFG-Phe causes the disruption of the R-
spine which results in a misalignment of the two lobes for the catalytic activity. 
Finally, other structural elements can characterize the kinase “off-state” such as a particular 
folding of the A-loop or the distortion of the Gly-rich loop.27-29,35-37 In any case, whereas 
kinases share very similar conformations in their catalytically active state, several structural 
differences can exist in their inactive forms and an univocal definition of the common 
features characterizing the kinase “off-state” is extremely challenging.29,34   
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Figure 1.2. Crystal structure of c-Jun N-terminal kinase (JNK) 3 in complex with β,γ-
methyleneadenosine 5′-triphosphate (AMP-PCP, yellow), PDB entry: 6EQ9. The protein backbone is 
displayed in gray while the diverse kinase structural elements mentioned in section 1.1.1. are 
highlighted with different colors: light green: hinge region; purple: αC-helix; salmon: Gly-rich loop; 
cyan: DFG motif; blue: catalytic loop; red: activation loop; magenta: conserved Lys (Lys93 in JNK3); 
Mg ion is displayed as a dark green sphere while polar interaction are shown as black dashed lines; 
due to high flexibility, most of the electron density for the activation loop was missing; protein 
structure on the left shows the typical bilobal folding of protein kinases whereas the close-up view 
shown on the right highlights the ATP cleft, wherein the side chains of key amino acids are displayed 
as sticks and some segments, including the Gly-rich loop, have been omitted for the sake of clarity; 
in the enlargement it is possible to observe the bidentate hydrogen bond of the AMP-PCP with the 
backbone atoms of Met149 and Glu147, as well as the interactions of Lys93 with the α and β 
phosphates and the salt bridge with Glu111; furthermore, the side chains of  the conserved DFG and 
HRD motifs are also shown.     
 
 
1.1.2.  Protein kinases as drug targets 
As previously mentioned, a deregulated activity of several kinases has been recognized 
having a causal role in the pathogenesis of different diseases.16  In the first instance, a strong 
evidence has connected aberrant phosphorylation with various forms of cancer, as kinases 
often constitute a switch in many signaling pathways regulating cell growth and 
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proliferation.38,39 Additionally, abnormal phosphotransfer activity has also been considered 
responsible for other complex pathological conditions as inflammatory, autoimmune and 
neurodegenerative diseases.40,41 The major role played by kinases in relevant diseases, along 
with their druggability,42 has prompted a remarkable endeavor in the discovery of protein 
kinase inhibitors.17 Since the FDA approval of the first small molecule kinase inhibitor 
Imatinib in 2001, more than 35 new small molecules have been approved at a constantly 
increasing rate.43,44 Although nearly the totality of molecules have been released as 
therapeutic agents for various forms of malignancies, the introduction of Tofacitinib45 
(Xeljanz) in 2012 as an immunomodulating agent has proven the possibility to broaden 
the field of applicability of kinase inhibitors.  
In the research of kinase inhibitors directed at the ATP binding site, two primary challenges 
need to be faced. Firstly, due to the similar structural features characterizing the members 
of the kinome especially with regard to the ATP cleft, it is particularly difficult to achieve 
molecules selectively inhibiting the target kinase. Moreover, inhibitors need to display a 
high potency in order to be able to compete with high intracellular ATP concentrations, 
typically ranging between 2 and 10 mM. Nevertheless, many kinase inhibitors have 
succeeded in overcoming these complications and can be classified according to their 
specific binding mode. A first criterion is based on the reversibility of the binding and 
permits to distinguish between covalent and non-covalent inhibitors. Additionally, non-
covalent/reversible inhibitors can be divided into five different subgroups (Type I, II, I½, 
III, IV) according to the targeted areas of the kinase (a graphical representation of the 
different classes of kinase inhibitors is outlined in Figure 1.4 at the end of this section). 
Type I inhibitors 
Type I inhibitors generally bind to the ATP cleft of the kinase in its active, DFG-in, αC-helix-
in conformation, wherein the Phe side chain of the DFG motif is buried in a hydrophobic 
area of the protein close to the αC-helix. Since this conformation of the kinase allows the 
binding with ATP, members of the type I class are considered fully ATP competitive.2,46,47 
A more correct description for the binding of type I inhibitors is that they can bind the ATP 
pocket regardless of the kinase activation state, thus not requiring a particular conformation 
of determined structural elements.48 
Given the close resemblance of the ATP binding pocket in the active kinases, a satisfactory 
selectivity was originally believed not to be achievable by targeting this conformation. 
However, the high success in therapy of type I inhibitors has demonstrated the possibility 
of reaching a clean selectivity profile by exploiting non-conserved features of specific 
kinases.  
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ATP competitive inhibitors typically follow a pharmacophore model developed by Traxler 
and coworkers49 which identifies five different subsites within the ATP binding pocket 
(Figure 1.3): 
 
Many of the FDA-approved kinase inhibitors belong to the type I class, such as the EGFR 
inhibitors Gefitinib (Iressa) and Erlotinib (Tarceva).26,43 
 
 
 Adenine region: 
 
 
in an analogous fashion as for ATP, this hydrophobic area 
allows the formation of hydrogen bonds between the 
inhibitor and the backbone amino acids of the hinge region. 
All type I inhibitors form at least one H-bond interaction in 
this area 
 Sugar/Ribose pocket: this region, accommodating the ribose of the ATP, presents 
mostly a hydrophilic character and offers the possibility of 
hydrogen bond formation which can improve the binding 
affinity 
 Phosphate region: this area is opened to the solvent and has a highly hydrophilic 
character. It is generally not addressed to increase the 
binding affinity but polar substituents occupying this area 
can be useful to improve the inhibitor solubility and 
pharmacokinetic (PK) properties  
 Hydrophobic region I: 
(HR I) 
also known as hydrophobic back pocket or selectivity pocket, 
this area opens in the N-terminal lobe and is not addressed 
by ATP. The access to this region is controlled by a specific 
amino acid residue of the N-lobe named “gatekeeper”. Since 
the gatekeeper and other residues surrounding this pocket 
are not highly conserved, this region can be targeted in order 
to achieve both selectivity for a specific kinase and increase 
in binding affinity    
 Hydrophobic region II: 
(HR II) 
this section consists in a solvent-exposed area which is not 
occupied by ATP when bound to the enzyme. As the amino 
acid composition is not conserved within the kinome it can 
be targeted by both hydrophobic and hydrophilic 
substituents to gain potency and selectivity  
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Figure 1.3. Representation of the Traxler’s pharmacophore model; the figure illustrates the 
endogenous substrate ATP in the binding site of JNK3. 
 
Type II inhibitors 
Inhibitors belonging to this category bind preferentially at the ATP pocket of the kinase in 
the inactive DFG-out conformation, resulting in its stabilization.50 As previously 
mentioned, this form occurs when the kinase is not phosphorylated at the A-loop and is 
characterized by a flip of the DFG-motif where the Phe side chain is shifted approximately 
10 Å away from the αC-helix. This results in the exposure of a hydrophobic cleft often 
named “deep pocket” or “allosteric site” which is absent in the ATP-bound kinase.50 Type 
II inhibitors typically form hydrogen bond contacts with the hinge region and target the 
deep pocket with a hydrophobic substituent. A hydrogen bond donor-acceptor pair 
(generally an amide or a urea) is also present immediately before this hydrophobic 
substituent and contributes to the positioning of the latter in the deep pocket by interacting 
with the αC-helix-Glu side chain and the DFG-Asp backbone.48 
Since the amino acid composition of the deep pocket is not conserved, type II inhibitors are 
considered to have a higher potential to achieve a clean selectivity profile. Moreover, not 
all the members of the kinase family are supposed to assume the DFG-out conformation, 
thus reducing the possible off-targets of this class of molecules.51 Nevertheless, despite an 
overall higher selectivity profile of this category, some type II inhibitors also showed a 
certain promiscuity within the kinome, and the original dogma claiming the elevated 
selectivity of this category of inhibitors had to be revised.52 
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As mentioned, type II inhibitors interact with some of the regions occupied by ATP and can 
be theoretically classified as ATP competitive. However, the inactive DFG-out 
conformation is known to have a significantly lower affinity for the endogenous substrate 
compared to the active form, thus reducing the ATP competition with the inhibitors.50 
Moreover, when analyzing the binding kinetics, it can be observed that type II inhibitors 
present a low association rate (kon), and a very low dissociation rate (koff), which increase 
the residence time on the target.53 Finally, studies analyzing the DFG-in and DFG-out forms 
of the p38α MAPK have highlighted how in the latter the conformation of the A-loop places 
the phosphorylation sites in a hidden position, probably preventing the activation by 
upstream kinases.54   
Various type II inhibitors can be found among the FDA approved kinase inhibitors as the 
aforementioned Abl-inhibitor Imatinib (Gleevec) and the VEGFR/PDGFR inhibitor 
Sorafenib (Nexavar).26,43  
 
Type I½ inhibitors 
This recent class of inhibitors was first described by Zuccotto et al. when observing the 
binding mode of certain published inhibitors.55 Such compounds, still addressing the ATP 
cleft, bind the kinase in an inactive DFG-in form wherein the αC-helix is shifted outwards 
from the ATP binding site. Despite adopting a DFG-in conformation, such state is 
catalytically non-competent, as the crucial Lys-Glu salt bridge is broken and the R-spine is 
disassembled. The movement of the αC-helix results as well in the formation of a 
hydrophobic cavity akin to the deep pocket of the DFG-out conformation, which can be 
addressed to improve selectivity. Type I½ inhibitors generally interact with the hinge via 
hydrogen bonds and point towards the back cavity, in some cases also addressing other 
areas defined by the Traxler’s pharmacophore (Figure 1.3). Some inhibitors of this class 
have been described not to reach the back pocket but instead forming hydrogen bonds with 
the αC-helix-Glu side chain and the DFG-Asp backbone, thus stabilizing the αC-helix-out 
conformation.56,57 The name attributed to this class suggests, therefore, the ability of these 
“hybrid” inhibitors to target the DFG-in conformation of the kinase by forming interactions 
analogous to the type II class. As in the case of type II inhibitors, the lower conservation of 
the back cavity has been hypothesized to represent a determining factor in the achievement 
of a higher selectivity. Furthermore, induction/selection of a particular conformation of the 
kinase is responsible for the slow binding kinetics of these compounds, significantly 
increasing the target residence time. As a result, the activity of these inhibitors is scarcely 
influenced by the ATP concentration, despite their classification as ATP competitive due to 
the occupancy of the nucleotide cleft.  
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Among the FDA approved inhibitors, examples for this class are represented by the EGFR 
inhibitor Lapatinib (Tykerb) and by the Raf inhibitor Vemurafenib (Zelboraf).26,43 
 
Type III inhibitors 
The definition of this class of inhibitors is particularly challenging and often not univocal, 
due to the heterogeneity of compounds composing it. Type III inhibitors are generally 
described to bind the kinase in an allosteric pocket adjacent to the ATP cleft and are 
therefore non ATP competitive, as a simultaneous binding of the inhibitor and the 
nucleotide is theoretically admitted.43 In some cases, these compounds can bind the deep 
pocket of DFG-out conformations without interacting with the hinge. Otherwise, these 
inhibitors can interact with the phosphoacceptor substrate binding site or exploit a novel 
binding site of specific kinases.58 These features provide the potential of an exquisite 
selectivity of action, accompanied by a lack of competition with the endogenous nucleotide 
substrate. However, inhibitors belonging to this class can hardly be rationally designed 
and, especially when aiming at the peptidic substrate binding site, this modality of 
inhibition is rarely achievable through small molecules. To date, only one FDA approved 
inhibitor can be included in this class, namely the MEK1/2 inhibitor Trametinib 
(Mekinist).  
When referring to the substrate binding site it is worth to mention that this area can be 
targeted by bivalent inhibitors which are presented in some classifications as type V 
inhibitors.59 These molecules consist of a classical small-molecule scaffold addressing the 
ATP pocket that is connected through a linker to a peptide portion, occupying the substrate 
binding site. To date, no molecule belonging to this class has been released.  
 
Type IV inhibitors 
The last class of reversible inhibitors includes those molecules binding the kinase in an 
allosteric site remote from the ATP binding cleft. Multiple binding modes are possible as 
each kinase possesses unique features when moving away from the catalytic site. Although 
the high potential of these molecules in terms of selectivity, it is rather uncommon to reach 
this modality of inhibition with small molecules due to the scarce presence of druggable 
pockets in this region of the protein. Examples of type IV approved inhibitors can be 
represented by the macrolide-based compounds Sirolimus/Rapamicine (Rapamune) and 
Everolimus (Certican), both targeting mTOR.   
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Covalent inhibitors 
Differently from reversible inhibitors, the compounds belonging to this category are able to 
covalently modify the target enzyme leading to a long-lasting inactivation, since the 
catalytic functionality can only be restored through ex novo synthesis of the protein.60 
Despite the existence of different classes of covalent inhibitors, targeted covalent inhibitors 
(TCIs) are the only ones which can be employed in the realm of kinases.61 Such molecules 
consist of a core scaffold binding the ATP cleft and a weakly electrophilic moiety which 
forms the covalent bond  with a specific nucleophilic amino acid. The generic mechanism 
of action of these inhibitors entails an initial noncovalent binding which allows the 
positioning of the tempered “warhead” in proximity of the target residue, followed by the 
formation of the covalent bond. For this reason, the activity of irreversible inhibitors 
depends both on their affinity for the enzyme (described by the Ki parameter) and on the 
rate of covalent bond formation (indicated by the kinact value).60,62  
The most commonly targeted residue in protein kinases is represented by Cys,63,64 although 
a few examples of inhibitors covalently modifying a Lys side chain have been reported.65,66 
Cys is the sole amino acid possessing a highly nucleophilic thiol group and is therefore 
prone to react with the weakly electrophilic warheads of TCIs. In addition, such amino acid 
is not involved in the catalytic mechanism of kinases, hence not conserved in the active site, 
offering the potential for a high degree of selectivity.64  
The electrophilic warhead has to be positioned at optimal distance and orientation with 
regard to the targeted Cys, and needs to possess a mild reactivity in order to not modify 
off-target nucleophiles. The covalent tag is most commonly represented by an α,β-
unsaturated carbonyl group which can react as a Michael’s acceptor in the conjugate 
addition of nucleophiles. However, other alkylating agents as α-haloketones or epoxides 
can be employed as well.61,67 
The interest on kinase covalent inhibitors has been increasingly rising during the last 
decade, as this class presents several advantages compared to classical reversible 
inhibitors.68 Firstly, the irreversible inactivation of the enzyme allows to uncouple the 
pharmacodynamic effect from the PK properties, conferring a high potency even at low 
concentrations and ensuring an extended duration of action which persists even after the 
drug has been cleared from the organism. This results in the possibility of administering 
lower inhibitor doses and with lower frequency. Moreover, as mentioned before, targeting 
an opportune non catalytic Cys residue allows to achieve a high level of selectivity, due to 
the low conservation of those areas not involved in the phosphorylation reaction.60-62 
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Figure 1.4. Schematic overview of the diverse types of kinase inhibitors. Each type is structurally 
exemplified by a FDA-approved inhibitor wherein the key structural features are highlighted using 
different colors; hinge-binding atoms are highlighted in yellow; for moieties occupying the HR I and 
the deep pocket cyan and salmon were used, respectively; hydrogen bond donor-acceptor pair is 
highlighted in blue while green was used for the covalent warhead; figure modified from Wu et al.43 
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A major concern in the development of covalent inhibitors regards the possibility of severe 
side effects deriving from the indiscriminate reactivity with off-targets. In particular, a 
primary risk consists of idiosyncratic adverse reactions which can be triggered by the 
formation of immunogenic protein-inhibitor adducts, a phenomenon known as 
haptenization.67 Nevertheless, the therapeutic success of FDA-approved covalent inhibitors 
like Afatinib (Giotrif) and Osimertinib (Tagrisso), targeting the epidermal growth factor 
receptor (EGFR), demonstrate the efficacy and tolerability of this class of inhibitors. 
 
1.2.  MAPKs 
MAPKs are a family of Ser/Thr kinases belonging to the CMGC group and constitute a key 
element of signal transduction pathways mediating the cellular response to a broad variety 
of extracellular stimuli. Based on sequence homology and functionality four subgroups 
have been observed within this family: the extracellular signal-regulated kinases (ERKs) 1 
and 2, the c-Jun N-terminal kinases (JNKs) 1, 2, and 3, the p38 MAPKs α, β, γ, and δ, and 
the ERK5.69 Each member is characterized by an overall specific activation mechanism and 
by distinct biological functions, although possibilities of cross-talk between different 
pathways have also been described.70  
All components of the MAPK family are activated through a phosphorylation cascade 
comprising the activation in series of at least two upstream kinases. This multistep 
mechanism offers the double advantage of amplifying the signal and allowing the 
integration of diverse signaling pathways.71 The transition of MAPKs to a catalytically 
active form is promoted by the double phosphorylation of a Thr and Tyr residues within a 
Thr-Xxx-Tyr motif, carried out by a substrate-specific MAPK kinase (MAPKK, MKK or 
MEK). MAPKKs are in turn activated via Ser/Thr phosphorylation by upstream kinases 
referred as MAPKK kinases (MAPKKKs) or MEK kinases (MEKKs). Activation of 
MAPKKKs/MEKKs can be triggered by a plethora of different stimuli which range from 
environmental stress stimuli (such as heat or osmotic shock, UV radiation or ischemic 
hypoxia) to the interaction of extracellular ligands (hormones, growth factors, cytokines, 
lipopolysaccharide) with specific receptors, generally represented by Tyr kinase receptors 
or G-protein coupled receptors (GPCRs). Each of these stimuli results in a distinct activation 
profile which can involve one or more MAPKs to a different extent.69-73 Figure 1.5 provides 
an overview of the different activation pathways of the MAPK family members. 
Once activated, each member of the MAPK family can phosphorylate a variety of different 
substrates resulting in the mediation of complex mechanisms as cell survival, proliferation, 
and differentiation. The vast majority of MAPK substrates is represented by transcription 
factors which upon phosphorylation can regulate the expression of specific genes; besides, 
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MAPK-mediated signaling can also involve the phosphorylation of cytoplasmic targets. 
Each MAPK presents specificity for a distinct subset of downstream targets although in 
some cases two different MAPKs can act on the same substrate.69,72,73 This substrate 
selectivity is reached not only by the recognition of a particular sequence surrounding the 
phosphorylation site (all MAPKs generally phosphorylate Ser or Thr residues followed by 
a Pro amino acid), but mostly thanks to docking motifs which confer complementarity 
between the MAPK and its specific substrates.72  
An additional important method in the regulation of the MAPK-mediated signaling 
pathways is the presence of scaffold proteins which coordinate the sequential activation 
within a MAPK module. In detail, such multi domain proteins can bind the different 
components of a phosphorylation cascade (MAPKKK, MAPKK, and MAPK) thereby 
promoting their spatial contiguity. The formation of this multi-enzyme complex increases 
the efficiency of the signal propagation compared to diffusion-based signaling and reduces 
the cross-talk between different pathways.74,75 
 
 
Figure 1.5. Schematic representation of MAPKs activation pathways. Figure was modified from 
Margutti et al.76 
 
1.2.1.  JNKs 
As already mentioned in the previous section, JNKs are Ser/Thr kinases constituting one 
of the four subgroups of the MAPK family.76 The first members of this subfamily were 
discovered in the 1990s and originally termed stress-activated protein kinases (SAPKs). The 
name JNKs was instead later given after the c-Jun transcription factor, which represents the 
first downstream target identified for these enzymes.77 Three different isoforms have been 
classified within this group, namely  JNK1 (also known as SAPK-γ/MAPK8), JNK2 (SAPK-
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α/MAPK9) and JNK3 (SAPK-β/MAPK10), encoded by the three distinct genes jnk1, jnk2, 
and jnk3. Each gene can then undergo alternative splicing, giving rise to a total of 10 JNK 
isoforms (four isoforms for both JNK1 and JNK2 and two for JNK3).78-80 Despite sharing a 
high structural similarity, the JNK isoforms exhibit different tissue distribution since the 
JNK1 and JNK2 are ubiquitously expressed, whereas the JNK3 is mostly restricted to the 
brain, heart and testes. Moreover, the different isoforms are characterized by a distinct 
substrate specificity, suggesting dissimilarities in their physiological functions.79,80  
In conformity with other members of the MAPK family, activation of JNKs is organized in 
signaling modules comprising tandem phosphorylation of three protein kinases (Figure 
1.5). More closely, activation of JNKs results from a concomitant phosphorylation of a Thr 
and a Tyr residues within a Thr-Pro-Tyr motif in the activation loop carried out by the two 
MAPKK MKK4 and MKK7.76,81 While MKK7 is specific for JNKs, MKK4 can also 
phosphorylate p38 MAPK members, albeit not being the main activator of these enzymes 
in vivo. The two upstream kinases MKK4 and MKK7 have proven to function in a 
synergistic manner so that both are required for the achievement of full JNK activation.82,83 
The MAPKK enzymes MKK4 and MKK7 can be phosphorylated by a multiplicity of 
upstream MAPKKK which in turn are triggered by a variety of stress stimuli including heat 
or osmotic shock, UV radiation, ischemia/reperfusion, and pro-inflammatory cytokines.81 
An additional level of regulation of the JNK activation pattern is constituted by scaffolding 
protein which, as previously mentioned, are able to bind the different elements of a 
phosphorylation cascade, thus favoring the signal transmission.74 Up to date, four different 
isoforms of the JNK-interacting protein (JIP) have been identified.81,84 
Activated JNK can phosphorylate a broad subset of downstream targets including both 
transcription factors and non-nuclear substrates.85 Phosphorylation of c-Jun, which takes 
part in the formation of the activation protein (AP)-1, increases the transcriptional activity 
of this complex. An analogous effect derives from the phosphorylation of the activating 
transcription factor (ATF)2 which modifies gene expression through the formation of 
dimers with members of the Jun family.86 Besides these two well-characterized pathways, 
JNKs can also act on additional nuclear targets, thereby modulating their effects on gene 
transcription (Figure 1.6). Furthermore, JNKs have demonstrated to phosphorylate 
cytosolic and mitochondrial substrates resulting in a modification of their functionality or 
in the regulation of their stability.85  
By means of diverse downstream targets, members of the JNK family are involved in 
various physiological functions. Firstly, these kinases are implicated in the regulation of 
cell survival/apoptosis in response to external stimuli. The role of JNKs in cell death has 
been described as bivalent, since it depends on the entity of the stimulus and on the signal 
integration with additional pathways. 
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Figure 1.6. Representation of the different substrates of JNK. The figure was realized using the 
information from Bogoyevitch and Kobe.85 
 
In general, a transient activation of JNKs seems to promote cell survival whereas a 
prolonged stimulation results in triggering the apoptotic process.82,87 Another significant 
role of the JNK proteins consists in the modulation of inflammatory response and immune 
system.88 In particular, mostly by promoting AP-1/ATF2-mediated gene expression, such 
enzymes contribute to the production of pro-inflammatory cytokines as tumor necrosis 
factor (TNF)-α and modulate the differentiation and activation of T-cells.89,90 Finally, as 
mostly shown in Drosophila, some members of the JNK family seem to be crucial in 
embryonal morphogenesis,88 this presumably explaining the non-viability of double 
jnk1/jnk2 knockout mice due to premature embryonal death.91 
Due to their involvement in important physiological processes, a dysregulation of the 
functionality of JNKs has been regarded as critical in diverse pathologic conditions.92 Since 
the JNK isoforms display dissimilarities regarding localization and substrate specificity, 
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each isoform can differently contribute to a particular disease as it could be pointed out by 
the selective silencing of one or more codifying genes.79   
 
Neurodegenerative diseases 
Within the last decades, a considerable evidence has connected the abnormal activity of the 
JNK family members with diverse neurodegenerative diseases such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Huntington’s disease, and multiple sclerosis, as well with 
neuronal death following ischemic episodes.93,94 
Increased expression of phosphorylated JNK has been observed in post-mortem brains as 
well as in biopsy samples of AD patients.95 Additionally, activated JNK is able to 
phosphorylate the amyloid precursor protein (APP) at Thr668 promoting its amyloidogenic 
cleavage into the β-amyloid (Aβ) peptide 42, which is considered the major responsible 
factor in the formation of Aβ plaques. The Tau protein can also be phosphorylated by the 
JNKs leading to the formation of neurofibrillary tangles representing, together with Aβ 
plaques, the principal histological hallmarks of AD.92,94,96 Finally, activation of the JNK 
pathway is also associated with neuroinflammation and apoptosis, thereby resulting in 
neuronal loss.96 
Analogously to AD, specimens of post-mortem brains from PD patients revealed an 
increased activation of the JNK-c-Jun pathway.93,94 In addition, mice knockout experiments 
permitted to observe a neuroprotective effect of JNK-deficiency against 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity, representing a typical animal 
model for PD. More closely, whereas jnk1 knockout mice showed similar results in 
comparison to the wild-type ones, single jnk2 or jnk3 deletion proved to significantly reduce 
cell loss after MPTP treatment. The neuroprotective effect was further enhanced following 
double jnk2/jnk3 knockout, hence confirming the pivotal role of these two isoforms in the 
progressive neurodegeneration characterizing PD.97 As previously mentioned, effects 
arising from the double jnk1/jnk2  knockout could not be observed due to non-viability of 
mice carrying this genetic deletion.91  
The recovery of blood circulation after a stroke/ischemia event can be associated to an 
extended tissue damage along with neuronal death in a “penumbra area” surrounding the 
site directly affected by the lack of oxygen supply. Such phenomenon is known as 
ischemia/reperfusion injury and is caused by different factors including inflammatory 
reaction and excitotoxicity.98 JNK3 deficiency has been demonstrated to protect neurons 
against hypoxia-driven excitotoxicity, as observed by the treatment of the cells with the Glu 
receptor agonist kainic acid or by simulating hypoxia in mice models.92-94,99 A similar effect 
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was instead not registered in case of single jnk2 or jnk1 knockout,99 suggesting a specific 
function of the JNK3 isoform in the response to excitotoxic insult. 
 
Cancer 
As mentioned before in this section, the JNK signaling pathway plays a bivalent role in the 
cellular life cycle, on one hand mediating cell survival and proliferation and on the other 
promoting stress-induced apoptosis. This dual behavior translates into a still unclear 
function of the JNK family members in cancer development.92,100 
The evidence of a pro-oncogenic role of JNKs has been provided by several studies 
demonstrating that these kinases take part in the Ras-mediated transformation by 
phosphorylating c-Jun, responsible for blocking the expression of the tumor suppressor 
p53.81,92,101,102 Members of the JNK family can also promote tumor survival, development, 
and dissemination by means of diverse mechanisms including cytokines production and 
angiogenesis.103 In addition, increased JNK1 or JNK2 activity has been observed in diverse 
cancer cell lines88 and a selective deletion of jnk1 or jnk2 in animal models has proven to 
reduce the development of certain types of malignancies.100-102 
At the same time, a significant number of experiments suggested a tumor suppressor 
activity of the JNKs, as it would also be expected from their well-characterized pro-
apoptotic function. As an example, selective isoform knockout in mice models led to an 
increased neoplastic proliferation104 or to a major susceptibility to develop tumors 
following exposure to carcinogens.105 In any case, the different behavior of JNKs as tumor 
suppressor or as tumor promoter seems to depend on the cell/tissue involved, as well as 
on the kinase isoform.100-102  
 
Metabolic diseases 
An association of JNK isoforms with obesity, insulin resistance, and type 2 diabetes has 
been highlighted in both in vitro and in vivo assays. In general, it can be observed that 
obesity and type 2 diabetes are associated with a chronic inflammatory condition of the 
adipose and liver tissues, wherein the cytokines and the free fatty acids produced may 
activate the JNK pathway.106 A first observation hinting the implication of JNKs in these 
metabolic pathologies is the increased activity of these enzymes in both dietary and 
genetically obese mice. In addition, selective ablation of jnk1 resulted in a reduced weight 
gain and lower adiposity of mice on a high-fat diet, along with lower plasma levels of 
glucose and insulin. Similar results could be detected on JNK1-deficient genetically obese 
mice, hence clarifying a role of this isoform in the obesity-induced insulin resistance.79,106 In 
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this pathological condition the molecular target of JNK1 was discovered to be the insulin 
receptor substrate 1, whose phosphorylation on Ser307 prevents the interaction with the 
insulin receptor.106,107 Analogous outcomes could not be reproduced by jnk2 knockout mice, 
which behaved analogously to the control. Such isoform might instead assume a role in the 
non-obese type 1 diabetes, as deletion of jnk2 seemed to reduce the immune response 
towards pancreatic islets and to decrease the apoptotic response of β-pancreatic cells.79,108 
 
Inflammatory diseases 
As already mentioned, JNKs are implicated in modulation of the inflammatory response 
and contribute to the regulation of the immune system by influencing the activity of T-
lymphocytes, macrophages, and mast-cells.92 These effects are mainly mediated by 
increasing the transcriptional activity of the AP-1 complex and of the ATF2. These factors 
can in turn increase the expression of pro-inflammatory cytokines as TNF-α and interleukin 
(IL)-2 and of other mediators of the inflammatory response as matrix metalloproteinases 
(MMPs).88,92 These aspects have suggested a participation of the JNK signaling in chronical 
inflammatory diseases which was confirmed by diverse studies.109-112 In particular, 
activation of the JNK pathway was observed in synovial cells and chondrocytes from 
patients affected by rheumatoid arthritis (RA) and osteoarthritis, respectively.109,110 
Additionally, treatment of synovial cells from RA patients with JNK inhibitors reduced the 
expression of MPPs involved in the degradation of joint cartilage, one of the symptoms 
characterizing this autoimmune disease.111  
Use of JNK inhibitors in an acute asthma mice model determined a decrease of immune 
cells in the peribronchial area and a reduced production of pro-inflammatory cytokines and 
immunoglobulin E compared to control, thereby suggesting an implication of the JNK 
pathway in this inflammatory pathology.112 
 
1.2.2.  JNK inhibition  
The key role assumed by the JNK pathway in several pathologic conditions has made these 
enzymes emerge as attractive drug targets, prompting an intense endeavor in the pursue 
of therapeutic inhibitors.113-115 Nevertheless, to date no JNK inhibitor has been introduced 
in therapy and only a scarce number of candidates has reached clinical phase (Table 1.1). 
While Tanzisertib, Bentamapimod, and CC-401 are classical type I inhibitors, binding 
reversibly to the ATP binding site, the retro-inverso peptide inhibitor XG-102 is able to 
occupy the docking site of the JIP scaffold protein, representing a less conventional strategy 
for JNK inhibition. 
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Table 1.1. JNK inhibitors in clinical trials  
Name(s) Structure Indication, phase, statusa 
CC-930 
Tanzisertib 
 
Pulmonary fibrosis, Phase II, 
Terminated116 
Discoid lupus erythematosus, 
Phase II, Terminated117 
XG-102 
D-JNKI-1 
AM-111 
 
Post cataract surgery 
inflammation, Phase III, 
Completed118 
Post cataract surgery 
inflammation and pain,  Phase III, 
Completed119 
Acute inner ear hearing loss, 
Phase III, Completed120 
Acute sudden sensorineural 
hearing loss, Phase III, 
Completed121  
Bentamapimod 
AS602801 
PGL5001  
Inflammatory endometriosis, 
Phase II, Completed122 
CC-401 
 
Refractory acute myelogenous 
leukemia, Phase I, Terminated123 
CC-90001 Undisclosed 
Idiopathic pulmonary fibrosis, 
Phase II, Ongoing/Recruiting124 
aFor each candidate only the clinical trials at the most advanced phase have been reported. 
 
The limited number of inhibitors reaching clinical phase underlines the necessity of new 
compounds targeting the JNKs. As already mentioned in section 1.1.2., the principal hurdle 
to overcome in the development of new kinase inhibitors consists in achieving high potency 
along with selectivity within the kinome. In particular, when aiming at JNK inhibition, a 
first challenge is represented by the achievement of selectivity of action over the 
structurally-related p38α MAPK.125 This well-known enzyme, belonging to the same family 
as JNKs, is analogously involved in signal transduction pathways triggered by stress 
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stimuli and has also demonstrated a clear involvement in inflammatory and 
neurodegenerative diseases, as well as in some types of malignancies.102,126,127 Due to the 
contribution of JNKs and p38α MAPK to akin pathological conditions, some studies 
pursued the dual inhibition of these targets as a potential strategy for the treatment of these 
disturbs.128 Nevertheless, the research of JNK selective inhibitors would still be desirable 
due to different reasons. In a first instance, the achievement of JNK specific inhibition 
would facilitate a better understanding of the role of these kinases in the diverse diseases 
and would help in assessing the therapeutic utility of selectively blocking this signaling 
pathway. Additionally, as suggested by the failure of some preclinical and clinical 
candidates targeting this enzyme, inhibition of p38α MAPK can potentially lead to 
additional side effects, mostly consisting in hepatic or central nervous system (CNS) 
toxicity, thus representing a risk for the safety profile of new compounds.129,130  
The two members of the MAPK family share a high sequence similarity at the ATP binding 
cleft, as outlined in Figure 1.7. JNK selective inhibitors need therefore to exploit the few 
structural differences in the amino acids composing the active site of the two enzymes.  
 
 
Figure 1.7. Comparison of JNK3 (light blue) vs p38α MAPK (green) sequences. Only amino acid 
residues located at the ATP binding site are displayed. Residues differing between the two sequences 
are highlighted in dark green. Sequence alignment was generated using EMBOSS-Needle tool from 
European Molecular Biology Laboratory (EMBL-EBI, Wellcome Genome Campus, Hinxton, 
Cambridgeshire, CB10 1SD, UK).  
 
A major difference between the JNK and p38α MAPK active sites lies in the “gatekeeper” 
residue which, as explained in section 1.1.2., is an amino acid limiting the access of 
inhibitors to the HR I. While the JNK gatekeeper consists of a Met residue which is 
conserved throughout the JNK isoforms (Met146 in JNK3), a smaller Thr residue occupies 
the same position in the p38α MAPK (Thr106), therefore delineating a wider cavity in the 
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latter enzyme. In addition, some of the amino acids circumscribing the JNK binding site, 
e.g. Ile70, Ile92, and Val196 (JNK3 numbering), are replaced by smaller residues in the p38α 
MAPK, thereby resulting in the formation of a narrower binding cleft of the former kinase. 
As an example, features like small size, planarity and hydrophobicity are considered the 
determinant for the selectivity of the early JNK inhibitor SP600125 over the p38α MAPK 
(Figure 1.8).131 However, despite reaching intra-MAPK selectivity, such anthrapyrazolone 
derivative has been described to possess a poor selectivity within the kinome,132 thus 
underlining the need of more specific interactions besides the aforementioned features. 
 
 
Figure 1.8. Structure and biological activities of SP600126. aData reported by Bennet et al.131 
 
As already mentioned in the previous paragraph, the three JNK isoforms diverge in 
substrate specificity, hence differently contributing to the onset and progression of 
pathological conditions. However, the involvement of each member of the JNK family 
could only be assessed so far by selective gene knockout, a method which does not fully 
allow to evaluate the effects resulting by the inhibition of these pathways in wild type 
organisms, e.g. impossibility to observe effects of double jnk1/jnk2 knockout. 
Consequently, the development of isoform-selective JNK inhibitors would provide a 
pharmacological tool to clearly identify the different involvement of the JNK isoforms in 
diseases, thus enabling the selection of the optimal therapeutic target within this subfamily. 
Unfortunately, JNK1, JNK2, and JNK3 share more than 80% sequence similarity and 
selectivity of action could not be reached so far. 
In the vast majority of cases, kinase inhibitors are evaluated through the use of activity 
assays, namely experiments which evaluate the influence of the inhibitor on the kinase 
phosphotransfer activity by comparison with an uninhibited positive control. In particular, 
an in-house enzyme-linked immunosorbent assay (ELISA), previously developed in the 
group of Prof. Laufer, was successfully employed to measure the inhibitory activity of 
compounds on JNK3 and p38α MAPK.133,134 This assay format allows to quantify the 
phosphorylation of the common target ATF2 due to the use of a horseradish peroxidase-
conjugated antibody that specifically binds the phosphorylated substrate.  Such method has 
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the clear advantage of providing a reliable and exhaustive assessment of the inhibitory 
activity in presence of the endogenous cofactor ATP and is still routinely employed, as it 
can be seen in the second part of this thesis, for the screening of newly synthesized 
compounds. Nevertheless, factors as low cost efficiency, non-easy handling, and long assay 
time limit the applicability of this procedure. Moreover, repeated separation and washing 
steps are comprised in this assay procedure (non-homogenous assay), hence preventing its 
applicability in high throughput screening (HTS) of compound libraries. Finally, the 
aforementioned ELISA-based assay has only been established for the p38α MAPK and for 
the JNK3, and currently no protocol has been developed for the JNK1 and JNK2 isoforms. 
Alternatively, biological activity of candidate inhibitors can also be assessed through 
binding assays measuring the stability of the enzyme-inhibitor complex. Although binding 
parameters do not necessarily imply inhibitory activity, a correlation between binding and 
inhibition can be assumed for those classes of inhibitors occupying the ATP cleft of the 
enzyme, as they prevent the interaction with the endogenous cofactor and thus the 
phosphotransfer reaction.  
 
1.2.3.  Fluorescence Polarization (FP) 
FP is a fluorescence-based technique which can be applied to diverse assay formats and 
thanks to its advantageous features like easy handling, cost efficiency, and amenability for 
HTS is being widely used in the field of drug discovery.135-137  
The theoretical basis of this method starts from the observation that the excitation of a 
fluorophore by plane-polarized light yields a polarized emission, by virtue of a 
phenomenon named photoselection. Considering a group of randomly-oriented 
fluorophores irradiated by polarized light, the photoselection derives from the increased 
probability of absorption of those molecules whose dipole is nearly parallel to the plane of 
the exciting radiation. In this way it is possible to “select” a population of excited 
fluorophores which, in case such molecules were immobilized, would emit light with a 
polarization analogous to the one of the source.138 However, molecules in solution are 
susceptible to Brownian motions, representing casual, non-ordered movements which 
determine an extremely rapid tumbling of the fluorophores. Since the rotational relaxation 
time ρ (time required by the molecule to rotate by an angle of 68.42°) has a much lower 
order of magnitude than the fluorophore lifetime τ (time window between absorption and 
emission), free fluorotracers in solution are unable to conserve the polarization achieved 
through photoselection. Conversely, when a fluorescently labeled molecule binds to a 
macromolecule, e.g., a protein, the whole complex has a longer rotational relaxation time 
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by virtue of the higher molecular weight, hence retaining the acquired polarization (Figure 
1.9).138-141  
 
 
Figure 1.9. Graphic explanation of the FP principle. τ represents the fluorophore lifetime, namely the 
time required for the excited fluorophore to emit the radiation. 
 
Upon excitation by plane-polarized light, the emitted radiation is split and directed into 
two detectors, which measure the intensities of the emission parallel and perpendicular to 
the plane of the source (I∕∕  and IꞱ, respectively).141 These two parameters are then used to 
calculate FP and/or fluorescence anisotropy (FA) through the equations 1.1 and 1.2, 
respectively. FA is a parameter having the same meaning as FP, although the latter finds 
wider use in biological applications. 
 
One of the multiple purposes of the FP principle is the use in competition binding assays. 
Such method consists in following the displacement of a fluorescently labeled probe by the 
candidate inhibitor through the measurement of the progressive FP signal decrease. Such 
method presents several advantages over the traditionally-employed radioligand-based 
binding assays such as improved safety and easy handling, not requiring separation and 
washing steps.142 The establishment of a FP-based binding assay requires several 
considerations concerning the probe design, the choice of the fluorophore, and the different 
assay parameters.139,140
  
  
 
2.  Objective of the Thesis Work 
 
The implication of JNKs in diverse pathological states has raised the interest toward the 
development of JNK selective inhibitors. Such molecules might be useful both as tools for 
better understanding the effective role of these enzymes in diseases, and as therapeutic 
agents for the treatment of JNK-related disturbs. Although several selective inhibitors for 
JNK have been reported, the scarce number of clinical candidates and the current absence 
of approved inhibitors highlight the need for new molecules targeting these enzymes.    
In a first instance, as an aid for the research of novel selective JNK inhibitors, a new 
competition binding assay was developed in order to ease the evaluation of the binding 
affinity of potential inhibitors of JNK3. Such assay is based on the technique of FP and 
required the design and the synthesis of a suitable fluorescently-labelled probe based on 
the pyridinylimidazole scaffold. After optimization, such assay was then extended to the 
other members of the JNK family, JNK1 and JNK2, as well as to the closely related p38α 
MAPK in order to provide a tool for a fast assessment of intra-MAPK and intra-JNK 
selectivity. The findings resulting from this part of the thesis work are included in 
Publications I and II. 
In the second part, different attempts were carried out to achieve selective inhibitors of JNK 
starting from a pyridinylimidazole-based lead. Numerous examples of molecules 
belonging to this class have been reported as potent inhibitors of the p38α MAPK and were 
obtained by optimization of the precursor SB203580 from SmithKline (Figure 2.1). An 
exhaustive summary on the synthesis routes and biological activity of this class of 
compounds is presented in Publication III. 
 
Figure 2.1. Examples of pyridinylimidazole derivatives as MAPK inhibitors. Data taken from 
Goettert et al.,133,134 Koch et al.,143 and Ansideri et al.144 (Publication I). 
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Besides p38α MAPK, pyridinylimidazole-based compounds are also able to inhibit 
members of the closely related JNK family and, as visible from Figure 2.1, alteration of the 
substitution pattern can result in a different selectivity profile of these derivatives.  For this 
reason, a series of structural modifications was performed on compound 1 both by altering 
the core scaffold and the substitution pattern (Figure 2.2), aimed at shifting the selectivity 
of this dual inhibitor towards the JNK (in particular, the focus was initially maintained on 
the JNK3, whereas the evaluation of intra-JNK selectivity was addressed only at a late 
stage). The broad set of performed structural modifications required the development of 
diverse synthesis strategies and is presented in Publications V and VII.  
  
 
Figure 2.2. Structural modifications of lead compound 1 involving different regions of the 
pyridinylimidazole scaffold. 
 
An alternative strategy which was pursued in order to obtain JNK selective inhibitors was 
the transformation of the reversible inhibitor 1 into a TCI by modification of the substituent 
at the pyridine-C2 position. Such approach aims at the formation of a covalent bond with 
the non-catalytic Cys154 (JNK3 numbering) which, as depicted in Figure 1.7, is not 
conserved in the p38α MAPK. This second strategy was prevalently carried out by Dr. Felix 
Muth and Dr. Ahmed El-Gokha and the outcomes are collected in Publication IV. 
  
 
3.  Results and Discussion 
 
3.1.  Development and optimization of an FP-based 
competition binding assay for JNK1, 2, and 3, and 
p38α MAPK 
 
3.1.1.  Design and synthesis of a new FP probe 
The first step in the establishment of a new FP-based competition binding assay consisted 
in the design of a suitable fluorescent probe for the target enzymes. Compound 1 (Figure 
2.1 and 3.1B) was discovered in a previous in-house study as a potent dual JNK3/p38α 
MAPK inhibitor, with IC50 values in the low nM range on both enzymes and was therefore 
selected as a potential precursor for the FP fluoroprobe.  
An extremely important aspect in projecting an FP-probe consists in the position of the 
labelling as the introduction of a bulky fluorescent tag might result in a loss of affinity of 
the probe for its targets. Munoz et al. reported in 2010 an FP probe for the p38α MAPK 
derived from the pyridinylimidazole-based reference compound SB203580.145 In such 
molecule, the fluorescent tag, represented by a fluorescein moiety, was linked at the 
imidazole-C2 position of the scaffold (compound 2, Figure 3.1A). Nevertheless, when 
planning a new probe suitable for both JNK3 and p38α MAPK, the aniline moiety at the 
pyridine-C2 position of compound 1 was assumed to be optimal for the installation of the 
fluorescent label. The reason for this lies in the well-known binding mode of 
pyridinylimidazole molecules, wherein the substituent at the pyridine-C2 position is 
located in the solvent-exposed HR II (a more detailed explanation of the binding mode of 
pyridinylimidazole-base inhibitors will be provided in section 3.2.1). Due to its opening on 
the outside of the protein, this area is presumably more prone to tolerate the large 
fluorescent group without substantial effects on the binding  
A second crucial setting concerns the choice of the fluorophore and the method of labeling. 
Fluorescein was selected as a fluorophore due to the affordable cost and to the availability 
of a broad range of derivatives, allowing the labeling of diverse functional groups. 
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Furthermore, virtually all plate readers are provided with the excitation/emission filters 
necessary for this fluorophore (approximately 490/525 nm). Finally, the short lifetime τ of 
this fluorescent marker (≈ 4 ns) is well-suited for the analysis of small ligands interacting 
with proteins heavier than 10 kDa.140 These features made fluorescein the first choice 
fluorescent dye employed in FP assays, as also recently reviewed by Hall and coworkers.135 
In particular, the selected dye was the fluorescein isothiocyanate (FITC) isomer 5’, which 
would easily react with the terminal aniline of compound 1 through the formation of a 
thiourea bridge (Figure 3.1B).  
 
 
Figure 3.1. Design of FP probes; A) probe 2 reported from Munoz et al.145 derived from standard 
inhibitor SB203580; B) probe 3 designed for a new FP-based competition binding assay derived from 
compound 1.  
 
An initial choice made consisted in avoiding the introduction of a spacer between the core 
scaffold and the fluorescent moiety, which was therefore directly linked to the terminal 
amino group of compound 1. The rationale behind this decision lies in the fact that although 
a spacer might increase the flexibility and reduce the impact of the bulky fluorophore on 
the binding interactions, it could also determine the rotational freedom of the fluorescent 
tag even when the probe is bound to the target.  This phenomenon is named “propeller 
effect” and can have detrimental outcomes on the FP measurement as it reduces the signal 
window between bound and unbound ligand.139,140 
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Before synthesis, the suitability of the designed probe 3 was confirmed by docking studies 
(Figure 3.2). Both in the case of JNK3 and p38α MAPK reasonable poses were generated 
wherein the fluorescent marker was positioned outside of the binding site, therefore 
seeming not to hinder the interactions of the core scaffold. 
 
 
Figure 3.2. Docking poses of probe 3 with JNK3 (left, PDB entry: 3FI3) and p38α MAPK (right, PDB 
entry: 1OUK).  
 
Besides the preparation of probe 3, four additional scaffolds and corresponding fluorescent 
probes were synthesized varying the substitution pattern around the imidazole ring 
(probes 3 and 8-11, Figure 3.3). This was carried out in order to broaden the subset of 
potential probes and therefore select the one displaying the best features in terms of 
applicability. All probes were tested in the aforementioned ELISA activity assay on both 
JNK3 and p38α MAPK and the results were compared with their precursors, aimed at 
observing the influence of the labelling on the inhibition potency (Figure 3.3). Among all 
the synthesized probes, compounds 3 and 10 seemed to display optimal features to serve 
as FP probes as they showed a high potency on the two enzymes which appeared to be only 
negligibly affected by the installation of the fluorescent dye. For this reason, such 
compounds were selected as candidates for the following assay optimization steps and the 
introduction of a spacer was not considered necessary. On the other hand, probes 8 and 9 
are characterized by a lower potency on JNK3 and by scarce or no inhibition of p38α MAPK 
and are therefore not suitable to be employed as dual probes. Moreover, in case of these 
two compounds the labelling with fluorescein seemed to have a considerable effect on the 
inhibitory activity, which decreased significantly on both kinases. Analogously to its 
precursor, probe 11 showed instead a moderate inhibition of both enzymes, with IC50 values 
in the triple-digit nM range. 
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Figure 3.3. Structures and biological activity of the synthesized probe candidates (compounds 3 and 
8-11) and their precursors (compounds 1 and 4-7). The synthetic schemes of compounds 1 and 4-7 
will be discussed in the second part of the thesis, section 3.2 and detailed procedures as well as 
analytical data can be found in Publication I (compounds 1 and 6), Publication IV (compound 4), 
or in the experimental section of this thesis (compounds 5 and 7); experimental procedures for the 
preparation of the fluorescent probes together with analytical data can be found in Publication I 
(probes 3 and 10), Publication VI (probe 11) or in the experimental section of this thesis (probes 8 
and 9). 
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3.1.2.  Probes characterization 
The second step performed in the development of an FP-based competition binding assay 
consisted of measuring the binding affinity of the synthesized probes to the selected targets 
JNK3 and p38α MAPK. In classical binding assays, e.g., radioligand-based assays, the Kd of 
a molecule is measured through saturation experiments wherein a fixed concentration of 
protein is titrated against increasing concentrations of ligand. This can be performed 
because by means of separation and washing steps the unbound ligand is removed before 
the reading and only the bound probe can be detected. Conversely, in the homogeneous 
FP-based binding assays, both bound and unbound species are present in the sample at the 
time of measurement and take part in the generation of the FP signal. Although the bound 
species has a much higher contribution on the observed polarization, increasing 
concentrations of free probe would result in a progressive reduction of the FP signal, thus 
hampering a correct Kd determination. This can be circumvented by modifying the assay 
settings through the titration of a fixed amount of fluoroprobe against increasing 
concentrations of protein.146 Unfortunately, this strategy requires high concentrations of 
protein in order to reach the saturation conditions which might represent a limitation in 
case of expensive targets. 
As discussed, the Kd of the synthesized probe was determined by titrating a 10 nM solution 
of probe with increasing concentrations of protein as schematized in Figure 3.4 (the range 
of concentrations was adapted for each probe in order to reach a full saturation curve). A 
well containing only fluoroprobe in assay buffer was also included as a negative control, 
establishing the signal baseline.  
Particularly important to mention is the use, for this assay, of an inactive form of both JNK3 
and p38α MAPK. Probe 3 represents a classical type I inhibitor which, as explained in 
section 1.1.2., can bind to the ATP site of the protein regardless of its activation state as the 
flexible DFG motif can assume both the in and out conformations. On the other hand, the 
use of a catalytically inactive kinase might represent an advantage, as it would allow the 
identification of other inhibitor classes binding preferentially this form, as type II and type 
I½ (type III inhibitors are presumably excluded since they do not directly occupy the ATP 
cleft and therefore might not be able to displace the probe).   
In case of probes 3 and 10, which had been selected for following optimization, FP signal 
was measured after 15, 30, and 60 min of incubation in order to obtain additional 
information regarding time of binding equilibrium onset and signal stability (Figure 3.5). 
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Figure 3.4. Microplate scheme for Kd determination of synthesized probes; experiment was 
performed three times in quadruplicate; in column 1 (light orange) a negative control containing 10 
nM solution of probe in assay buffer was used, representing the baseline of the FP signal; the green 
gradient in columns 2-12 represents the probe with increasing concentrations of protein;  
 
Both probes showed high binding affinity for the two tested enzymes with Kd values in the 
single digit nM range. Moreover, both compounds were characterized by a rapid binding 
equilibrium onset and the measured Kd values appeared to be stable over time, with only a 
negligible variation after 60 min incubation. An incubation time of 30 min and its 
corresponding probe Kd values were selected for the further development of the assay.  
In order to confirm the binding profile of probes 3 and 10 on JNK3 and p38α MAPK, an 
independent binding assay was performed through isothermal titration calorimetry (ITC). 
The two probes showed again high affinity for their targets with Kd values in the low 
double-digit nM range (3: Kd(JNK3) = 25 nM, Kd(p38α MAPK) = 35 nM; 10: Kd(JNK3) = 20 nM, Kd(p38α 
MAPK) = 33 nM). The slight differences in the Kd absolute value in comparison with values 
reported in Figure 3.5 can be attributed to intrinsic differences of the two assay methods as 
well as to dissimilarities in the protocols used. Nevertheless, the high affinity and the 
similar binding features of probes 3 and 10 were confirmed. 
Given the nearly identical inhibition profile of the two probes, and needing to promote only 
one fluoroprobe to the following steps, compound 10 was discarded only based on a lower 
yield of its synthesis route and the optimization was carried out exclusively on probe 3. 
 
 
 
 
 
3.  RESULTS AND DISCUSSION  47 
 
1 0 -1 0 1 0 -9 1 0 -8 1 0 -7
0
2 5
5 0
7 5
1 0 0
1 5  m in  K d  =  5 .4   1 .0  n M
3 0  m in  K d  =  5 .7   1 .1  n M
6 0  m in  K d =  6 .2   1 .2  n M
p 3 8   M A P K  c o n c e n tra t io n  (M )
n
o
r
m
a
li
z
e
d
 p
o
la
r
iz
a
ti
o
n
 (
%
)
1 0 -1 0 1 0 -9 1 0 -8 1 0 -7
0
2 5
5 0
7 5
1 0 0
1 5  m in  K d  =  6 .2   0 .1  n M
3 0  m in  K d  =  6 .5   0 .2  n M
6 0  m in  K d =  7 .2   0 .3  n M
p 3 8 a  M A P K  c o n c e n tra t io n  (M )
n
o
r
m
a
li
z
e
d
 p
o
la
r
iz
a
ti
o
n
 (
%
)
1 0 -1 0 1 0 -9 1 0 -8 1 0 -7
0
2 5
5 0
7 5
1 0 0
1 5  m in  K d  =  2 .3   0 .1  n M
3 0  m in  K d  =  2 .6   0 .1  n M
6 0  m in  K d =  3 .2   0 .1  n M
J N K 3  c o n c e n tra tio n  (M )
n
o
r
m
a
li
z
e
d
 p
o
la
r
iz
a
ti
o
n
 (
%
)
P ro b e  3
1 0
-1 0
1 0
-9
1 0
-8
1 0
-7
0
2 5
5 0
7 5
1 0 0
1 5  m in  K d  =  2 .7   0 .2  n M
3 0  m in  K d  =  3 .0   0 .2  n M
6 0  m in  K d =  4 .0   0 .3  n M
J N K 3  c o n c e n tra t io n
n
o
r
m
a
li
z
e
d
 p
o
la
r
iz
a
ti
o
n
 (
%
)
J N K 3 p 3 8   M A P K
p 3 8   M A P KJ N K 3
P ro b e  1 0
 
Figure 3.5. Titration curves and corresponding Kd values of probes 3 and 10 on JNK3 and p38α 
MAPK measured at different incubation times. Each experiment was performed 3 times in 
quadruplicate; data points represent mean value ± SD; this and other graphs henceforth were 
obtained using the software GraphPad Prism version 7.3 for Windows (GraphPad Software, La Jolla 
California USA, www.graphpad.com).  
 
Although not being chosen for further optimization, the Kd values of the other synthesized 
probes (compounds 8, 9 and 11) on JNK3 were also determined in order to achieve the 
characterization of all the prepared fluorotracers. For the titration experiments an 
incubation time of 30 min was selected and results are presented in Table 3.1.  
 
Table 3.1. Kd values of compounds 8, 9, and 11 on JNK3. 
Cpd n. 
Kd on JNK3 (nM) 
(mean value ± SD) 
8 188.0 ± 3.0  
9 44.6 ± 6.9 
11 11.4 ± 6.6 
Experiments were performed three 
times in quadruplicate 
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3.1.3.  Assay conditions optimization 
After determining the binding affinity of the selected probe 3 for JNK3 and p38α MAPK an 
additional experiment was carried out in order to choose the final settings which would 
improve the performance of the assay. In detail, given for probe 3 the values of Kd(JNK3) = 3.0 
± 0.2 nM and Kd(p38α MAPK) = 5.7 ± 1.1 nM, a 5 nM concentration of compound 3 was chosen 
to be employed in the competition binding assay. This is in line with practical 
considerations in the development of an FP-based binding assay, suggesting to reduce the 
fluoroprobe concentration as much as possible, not exceeding twice the Kd value.140    
A second crucial parameter in defining the assay efficiency is represented by the protein 
concentration. Performing the competition assay at saturation conditions, where all the 
fluoroprobe molecules are bound to the target, would obviously allow to obtain the 
maximum signal window. However, these stoichiometric conditions would imply high 
levels of unbound protein which would decrease the responsivity of the system to the 
addition of competitors, thus reducing the sensitivity of the assay.147 In order to determine 
the optimal protein concentration a titration experiment analogous to the previous one was 
performed using a 5 nM concentration of probe 3 and 30 min of incubation time (Figure 
3.6). As suggested in FP-assay development guidelines,140 the optimal protein concentration 
should produce, at the probe concentration selected for the assay, an increase in 
polarization lying approximately between 50 and 80% of the titration curve. This range is 
sufficiently away from the saturation conditions to provide sensitivity to the assay, being 
at the same time able to yield an appropriate signal window (dynamic range). The titration 
experiments displayed in Figure 3.6 permitted to identify 10 nM as the optimal 
concentration of both JNK3 and p38α MAPK to be used in the competition assay. Such 
concentration yielded for both enzymes an increase in polarization close to 80%, with the 
satisfactory signal windows of approximately 140 and 160 mP for JNK3 and p38α MAPK, 
respectively (it is important to mention that although FP is a dimensionless parameter, 
millipolarization units or mP are commonly used to define its value).  
To sum up, the parameters which were selected to be employed in the FP-based 
competition binding assay were: 
 5 nM concentration of probe 3 
 10 nM concentration of protein 
 30 min incubation time 
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Figure 3.6. Titration experiments for determining the optimal protein concentration; both assays 
were performed using 5 nM concentration of probe 3. The green band represents the optimal protein 
concentration range while the vertical dashed line indicates the selected protein concentration of 10 
nM. 
3.1.4.  Assay validation 
After setting the different parameters aimed at optimizing the assay performance, the 
competition binding assay was run using the precursor of probe 3 (compound 1) to displace 
the fluorotracer. The use of the unlabeled probe generally represents the “gold standard” 
for the validation of this assay format as the interactions of the target with the labeled and 
unlabeled compounds should be analogous.140 The assay was performed as depicted in 
Figure 3.7 by titrating a fixed concentration of probe 3 (5 nM) and JNK3 or p38α MAPK (10 
nM) with increasing concentrations of the tested compound. For each compound tested a 
well containing probe and protein and a well containing probe in assay buffer were also 
added as positive and negative control, respectively.  
 
 
Figure 3.7. Plate scheme for the competition binding assay; each compound was tested in 
quadruplicate; column 1 (light orange) represents a positive control consisting in probe and protein 
while a negative control containing only probe in assay buffer is placed in column 12 (yellow). The 
green and blue gradients in columns 2-11 represent increasing concentrations of two different 
compounds. 
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Compound 1 succeeded in displacing probe 3 in a dose-dependent manner both on JNK3 
and p38α MAPK (Figure 3.8), in both cases resulting in IC50 values in the double-digit nM 
range (IC50(JNK3)= 20 nM; IC50(p38α MAPK)= 51 nM). As the IC50 value is strictly dependent on 
the assay conditions e.g, probe affinity or concentration of probe and protein, a common 
practice consists in the conversion of IC50 values into the inhibition constant (Ki). A well-
known tool for transforming IC50 values into Ki is represented by the Cheng-Prusoff 
equation148 (Eq. 3.1). This formula was developed for competitive inhibitors of Michaelis-
Menten enzymes and was subsequently adapted to be applied to competition binding 
assays as well (Eq. 3.2) with the terms [L] and Kd referring to concentration and affinity of 
the labeled ligand, respectively.  
  
 
However, the aforementioned equations are not suitable to be directly applied to FP-based 
competitive binding assay, due to an incompatibility with the assumptions on which they 
are based. For this reason, a modified Cheng-Prusoff equation suitable for FP binding 
assays was developed by Nikolovska-Coleska et al.149 (Eq. 3.3) with the parameters [I]50, 
[L]50, and [P]0 indicating the concentration of free inhibitor at 50% inhibition, concentration 
of unbound labeled ligand at 50% inhibition, and concentration of free protein at 0% 
inhibition, respectively. 
 
Such equation was also implemented in a web-based tool allowing an easy conversion of 
the IC50 values into Ki by simple input of the assay settings.150 
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Figure 3.8. Competition binding assay and Ki values of compound 1 on JNK3 and p38α MAPK; each 
experiment was performed three times in quadruplicate; data points represent mean values ± SD; Ki 
values indicate mean value ± SEM.  
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The Ki values obtained by the assay of the probe precursor 1 on JNK3 and p38α MAPK 
(Figure 3.8) proved to be extremely close to the Kd values of probe 3 on the same enzymes 
(Figure 3.5), demonstrating the low impact of the fluorescent tag on binding interactions. 
An additional method for validating the developed assay consisted of screening a small 
library of compounds and comparing the obtained binding data with the results deriving 
from a different assay. In particular, given the availability of an in-house ELISA activity 
assay for both JNK3 and p38α MAPK (already mentioned in section 1.2.2.), this method was 
chosen for comparison. The set of compounds was selected in order to achieve a broad 
structural diversity alongside with different potency on the two target enzymes (Figure 
3.9). This consisted therefore of a series of pyridinylimidazole-based inhibitors, including 
the reference compounds SB203580 and ML3403, and non-pyridinylimidazole derivatives, 
such as pyridinylquinoxaline 16. In addition, reference compound SP600125, 
aminopyrimidine 15, and clinical candidate AS601245 were chosen to be tested uniquely 
on JNK3, whereas high quality probe Skepinone-L and clinical candidate SB681323 were 
selected for the p38α MAPK assay. An initial screening on the selected compound set 
consisted in analyzing their autofluorescence at the excitation and emission wavelengths 
used for the fluorescein (480 and 530 nm, respectively). Emission of fluorescence at the 
aforementioned wavelengths would indeed create interference with the FP signal 
measurement and would hamper the correct performance of the assay. Compounds 
showing fluorescence cannot therefore be tested with the developed assay. Fluorescence of 
compounds was measured and compared with the positive and negative controls 
containing a 5 nM probe concentration and only DMSO, respectively. 
 
Figure 3.9. Set of compounds selected for the assay validation 
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Although most of the compounds revealed to be suitable for the following assay, 
derivatives SP600125 and AS601245 emitted a significantly higher fluorescence than the 
negative control, thus needing to be excluded from the FP assay. Remaining compounds 
were tested on the two enzymes and IC50 values were converted to Ki using the 
aforementioned modified Cheng-Prusoff equation (Eq. 3.3). Results of the screening on the 
set of compounds are reported in Table 3.2, together with the IC50 values of the same 
compounds in the in house ELISA assay. As expected, given the high difference in the assay 
formats, an equivalence in the numeric value of inhibition data could not be observed.  
Table 3.2. Biological activities of selected compounds measured in the FP assay 
  JNK3  p38 MAPK 
Cpd. 
 ELISA assay 
IC50 ± SEMa [nM] 
FP assay 
Ki ± SEMa [nM] 
 ELISA assay 
IC50 ± SEMa [nM] 
FP assay 
Ki ± SEMa [nM] 
SB203580  727 ± 28b 167 ± 10  50 ± 0.4c 56 ± 1 
1  24 ± 1 3 ± 0.2  17 ± 0.4 14 ± 2 
ML3403  176 ± 2 40 ± 6  40 ± 5d 38 ± 1 
LN950  181 ± 4 13 ± 1  11 ± 0.9e 4 ± 1 
12  370 ± 13 49 ± 2  53 ± 4  39 ± 9 
13  742 ± 12 142 ± 18  170 ± 10 141 ± 10 
14  67 ± 2 5 ± 1  97 ± 8 61 ± 7 
15  147 ± 5  29 ± 2  n.t.f n.t. 
16  3,950 ± 200g 1,041 ± 32  81 ± 5g 350 ± 10  
Skepinone-L  n.t. n.t.  5 ± 2h 4.2 ± 0.4 
SB681323  n.t. n.t.  13 ± 0.1 7 ± 0.1 
an = 3. bdata previously reported by Goettert et al.134; cdata previously reported by Goettert et 
al.133; ddata previously reported by Laufer et al.151; edata previously reported by Koch et al.143; 
fn.t., not tested; gdata previously reported by Koch et al.152; hdata previously reported by 
Fischer et al.153.  
 
Nevertheless, aimed at assessing a correlation between the results of the two different assay 
systems, the inhibition data reported in Table 3.2 were analyzed by linear regression. 
Results depicted in Figure 3.10 demonstrate that, despite the use of kinases in a different 
activation state, the two assay formats show a high correlation, with R2 values of 0.9555 and 
0.8447 for JNK3 and p38α MAPK, respectively.  
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Figure 3.10. Linear regression analysis of inhibition values reported in Table 3.2. 
Besides confirming the validity of the developed assay, this observed correlation suggests 
a potential use of the FP-based competitive binding assay as a fast and relatively 
inexpensive pre-screening method for novel compounds, permitting to advance only most 
promising compounds to the activity assay. In this regard, it is worth to mention that the 
developed assay was employed to assess the influence of halogen bonding on JNK3 
inhibition, this representing the first example of an FP-based binding assay on this 
enzyme.154 
 
3.1.5.  Applicability to the HTS format 
As mentioned in the end of the previous section, the correlation between the developed 
assay and the in-house ELISA assay could be utilized for the fast estimation of the inhibitory 
activity of large compound libraries, hence allowing to discard inactive compounds at an 
early stage. For this reason, the applicability of the developed binding assay in an HTS 
format was evaluated. This is also possible thanks to the homogeneity of the FP-assay which 
allows its performance by simple addition of reactants (mix and measure), thus avoiding 
separation and washing steps. For the validation a procedure reported in an assay guidance 
manual from the national center for biotechnology information (NCBI) was used.155 In 
particular, experiments were performed following the interleaved plate protocol on a 96-
well plate. This consists of analyzing the intra- and inter-plate stability of three different 
kinds of signals: 
 “Max”: highest FP signal; well containing 5 nM probe and 10 nM protein in assay 
buffer 
 “Min”: lowest FP signal; well containing 5 nM probe, 10 nM protein, and a 
concentration of a reference compound (in this case the probe precursor 
1) at a concentration known to completely displace the probe 
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 “Mid”: intermediate signal; well containing 5 nM probe, 10 nM protein and a 
concentration of compound 1 close to the IC50 value on the 
corresponding enzyme 
The assay on each enzyme must be performed in three independent runs on different days, 
each time following a different pipetting pattern described in the manual so that each signal 
is measured in all possible plate positions after three repetitions. 
The aim of HTS validation is to assess whether the assay presents a sufficient 
reproducibility of results and an adequate signal window width in order to avoid or reduce 
the occurrence of false positives or false negatives in an HTS screening. The acceptance 
criteria are in a first instance based on the conformity of calculated parameters within 
defined threshold values:  
 Coefficient of variation (CV)  20% for each of the three signals in every plate 
 Z factor > 0.4 for every plate 
 SD for the normalized %inhibition of the Mid value  20% in every plate 
 Normalized %inhibition for Mid value between 30 and 70% within three days 
 No difference >15% in the normalized %inhibition of two different days 
 
 
Table 3.3. Summary of HTS validation experiments  
JNK3 
day 
 Max  Min  Mid  
Z-
factor  FP value (mP) 
(mean ± SD)  
CV 
 FP value (mP) 
(mean ± SD) 
CV 
 FP value (mP) 
(mean ± SD) 
CV 
%inhibition 
(mean ± SD) 
 
1 
 
300.3 ± 2.2 0.7% 
 
161.7 ± 2.8 1.7% 
 
220.8 ± 4.0 1.8% 57.4% ± 2.9% 
 
0.89 
2 
 
300.5 ± 3.8 1.2% 
 
151.3 ± 3.3 2.2% 
 
210.7 ± 5.3 2.5% 60.2% ± 3.5% 
 
0.86 
3 
 
298.0 ± 3.8 1.2% 
 
143.1 ± 3.2 2.2% 
 
195.1 ± 5.0 2.5% 66.5% ± 3.2% 
 
0.86 
p38α MAPK 
day 
 
Max 
 
Min 
 
Mid 
 
Z-
factor  FP value (mP) 
(mean ± SD)  
CV 
 FP value (mP) 
(mean ± SD) 
CV 
 FP value (mP) 
(mean ± SD) 
CV 
%inhibition 
(mean ± SD) 
 
1 
 
296.1 ± 2.7 0.9% 
 
122.4 ± 4.3 3.5% 
 
256.9 ± 3.4 1.3% 22.6% ± 2.0% 
 
0.88 
2 
 
304.9 ± 4.1 1.3% 
 
134.9 ± 3.5 2.6% 
 
226.9 ± 2.9 1.3% 45.9% ± 1.7% 
 
0.86 
3 
 
291.9 ± 6.9 2.3% 
 
124.9 ± 4.6 3.6% 
 
214.6 ± 4.7 2.2% 46.3% ± 2.8% 
 
0.79 
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The results of the HTS validation experiments on both enzymes, displayed in Table 3.3, 
demonstrate that nearly all the acceptance criteria are satisfied. The unique slight deviation 
is represented by the day 1 experiment on p38α MAPK wherein the measured value of 
%inhibition was lower than 30%, causing therefore a difference >15% with the results of the 
following days. However, the requirement of a Mid value lying within 30 and 70% is 
described more as an ideal than as a compulsory criterion and the suitability of the 
developed assays for the HTS format appears in any case to be clear from the other 
calculated parameters. In this regard, worth to mention is the very high Z-factor registered 
in all assay runs, indicating a broad signal window and a small intra-plate variability of 
results. 
The assessment of the suitability for the HTS assay was then completed by a visual 
observation of the graphs resulting from the different experiments. In detail, data points 
were plotted following the two different patterns “by row, then by column” and “by 
column, then by row” and neither drift nor edge effect could be detected, thus confirming 
the applicability of the developed assay for the HTS format. 
 
3.1.6.  Extension of the developed assay to the JNK1 and JNK2  
As discussed in section 1.2.2., intra-JNK selectivity of new inhibitors is still representing an 
unsatisfied need as only compounds displaying a slight preference for one of the three JNK 
isoforms have been reported to date.114 In order to easily evaluate the selectivity of novel 
inhibitors within the JNK family, the FP-based competition binding assay previously 
developed for the JNK3 and p38α MAPK was extended to the remaining isoforms of the 
JNK subgroup. This was possible thanks to the poor selectivity of the synthesized probe 3, 
a feature which resulted beneficial in broadening its versatility of use. 
 
Probe Kd determination and optimization of assay parameters 
In an analogous fashion as for the JNK3 and the p38α MAPK (section 3.1.2), the affinity of 
probe 3 for JNK1 and JNK2 was determined by titrating a fixed concentration of 
fluoroprobe with increasing concentrations of protein. In order to evaluate time-
dependence of the results, the FP signal was measured after incubation times of 15, 30, 60, 
and 120 min (Figure 3.11).  In order to maintain similar settings between the assay protocols 
on different isoforms, a probe concentration of 5 nM was used in the titration experiments. 
As it is possible to observe from Figure 3.11, probe 3 seems to have a lower affinity for JNK1 
and 2 in comparison with JNK3. Measurements conducted at different time points 
permitted to assess an overall stability of the Kd signal over time, with a negligible increase 
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at incubation times higher than 60 min. As in the case of the aforementioned assay, the Kd 
value measured after 30 min incubation was selected for both enzymes. The titration 
experiments were then directly used for the determination of the optimal protein 
concentration, as previously discussed. This led to select kinase concentrations of 50 and 30 
nM for JNK1 and JNK2, respectively, both yielding an increase in polarization of 
approximately 80%. 
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Figure 3.11. Titration of probe 3 with JNK1 and JNK2. Experiments were performed three times in 
quadruplicate; data points and resulting Kd values are reported as mean value ± SD; dashed lines 
represent the range of protein concentrations producing an increase in polarization between 50 and 
80%. 
 
Assay validation 
The first experiment to assess the validity of the assays consisted, as previously, in testing 
the probe precursor 1 in a competitive binding assay using the selected settings. Conversion 
of the resulting IC50 values through the aforementioned modified Cheng-Prusoff equation 
yielded Ki values in the low double-digit nM range (1, Ki(JNK1) = 19 nM; Ki(JNK2) = 12 nM), 
very close to the Kd of probe 3 for the same enzymes. However, unlike in the case of JNK3 
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and p38α MAPK, the in-house ELISA assay was not developed for the JNK1 and JNK2 and 
a direct comparison of the results was therefore not possible. For this reason, the validation 
of the FP assay on JNK1 and JNK2 required this time the comparison of the binding results 
with literature values of reference compounds tested on the same enzymes. For this 
purpose four different ATP-competitive JNK standard inhibitors were selected (IQ-1S,156 
JNK inhibitor VIII,157 SR-3576,158 and SR-3306159). As in the previous case the selection was 
aimed at maximizing the chemical diversity. Moreover, additional factors had to been taken 
in account such as the commercial availability and the existence of inhibition data for both 
JNK isoforms on the same assay format. As these compounds did not show intrinsic 
fluorescence at the wavelengths used in the assay readout, they all were tested in the 
competition binding assay on the two enzymes (Table 3.4).  
 
Table 3.4. Ki values resulting from the FP-assay in comparison with literature data 
Compound 
 JNK1  JNK2 
 Ki FP assay (nM) 
(mean ± SDa)  
Literature 
data (nM) 
 Ki FP assay (nM) 
(mean ± SDa)  
Literature 
data (nM) 
1  19 ± 4 n.rb  12 ± 1 n.r. 
IQ-1S  311 ± 43 390 (Kd)c 
 390 ± 38 360 (Kd)c 
JNK inhibitor VIII  48 ± 12 2 (Ki)d 
 35 ± 5 4 (Ki)d 
SR3576  40 ± 6 170 (IC50)e 
 8 ± 2 n.r. 
SR3306  79 ± 12 67 ± 19 (IC50)f 
 215 ± 57 283 ± 3 (IC50)f 
a n = 3; bn.r., data not reported in literature; cdata reported by Schepetkin et al.156, SD not 
reported; ddata reported by Szczepankiewicz et al.157, SD not reported; edata reported by 
Kamenecka et al.158, SD not reported; fdata reported by Chambers et al.160. 
 
 
Although in most cases the obtained Ki values seem to correspond to reported results of 
JNK standard inhibitors, the diversity of assay formats employed, type of the reported 
inhibition data (Ki, Kd, IC50), and activation state of the protein used do not allow a direct 
comparison of the results’ absolute values. Nevertheless, it can be stated that, when 
inhibition data were reported for both JNK isoforms, the results obtained by the FP-based 
binding assay follow an analogous trend as the published ones. However, due to the 
different assay layouts of the published results and to the scarceness of tested inhibitors, a 
linear regression analysis could not be performed to support the correlation between the 
assays.  
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3.2.  Optimization of a pyridinylimidazole scaffold 
aimed at achieving selectivity on JNK 
 
3.2.1. Selection of a suitable lead compound 
With the objective of reaching a selective inhibition of the JNKs, compound 1 (IC50(JNK3)= 24 
nM; IC50(p38α MAPK)= 17 nM) was selected as a starting point for subsequent modifications. 
However, this derivative cannot represent a lead compound “as such” due to the presence 
of the free terminal aniline group. This moiety is recognized by the ZINC15 pattern tool161 
as a potential responsible for compound aggregation and might therefore convert the 
compound into a so-called “pan assay interference compound” (PAIN). The latter represent 
a category of compounds which by means of their chemical/physical properties are able to 
interfere with common assay formats or to react non-specifically with the target, thereby 
displaying a misleading biological activity.162,163 Since aggregation constitutes one of the 
most common causes of assay interference163 the p-phenylendiamino group located at the 
pyridine-C2 position of compound 1 was replaced with a 4-morpholinoaniline moiety 
(compound 17, Figure 3.12) which has been previously reported as a suitable substituent in 
this position.164 The akin potency of the new derivative 17 seemed in any case to confirm 
the absence of an interference mechanism of the free terminal aniline substituent, thus 
validating the inhibitory activity of 1 on the tested enzymes. Nevertheless, the new 4-
morpholinoaniline group was maintained constant when modifying other regions of the 
scaffold in order to rule out aggregation-driven interference which might arise from the 
combination of the p-phenylendiamino substituent with other moieties. 
 
 
Figure 3.12. Replacement of the p-phenylendiamino group of compound 1 with the 4-
morpholinoaniline moiety, affording compound 17. IC50 values shown henceforth derive from the 
biological evaluation of compounds using the aforementioned ELISA activity assays.133,134 
 
From the synthetic point of view, derivatives 1 and 17 could be prepared following a 
procedure described by Laufer and coworkers165 wherein the construction of the 2-
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sulfanylimidazole is based on the Marckwald imidazole synthesis166 (Scheme 3.1). 
Introduction of the aromatic amine was then carried out by acid-catalyzed nucleophilic 
aromatic substitution (SnAr). 
 
Scheme 3.1. Synthesis route of compounds 1 and 17 
Several studies on pyridinylimidazole-based inhibitors, also supported by X-ray 
crystallography, have provided a wide knowledge regarding the binding mode of this class 
of molecules to both p38α MAPK and JNK3 (Figure 3.13). In particular, these molecules are 
known to form a bidentate hydrogen bond interaction with the backbone amino acid of the 
hinge region through the 2-aminopyridine donor/acceptor pair. In addition, the aromatic 
substituent at the imidazole-C4(5) position is known to be accommodated in the 
hydrophobic back pocket or HR I (see section 1.1.2) while the substituent at the pyridine-
C2 position occupies the solvent exposed HR II. Moreover, the imidazole N atom distal to 
the pyridine ring forms a direct or H2O mediated hydrogen bond with the conserved lysine 
side chain of the N lobe. Finally, the 2-methylsulfanyl moiety stretches towards the 
phosphate region. 
 
Figure 3.13. Binding mode of pyridinylimidazole-based inhibitors in the binding site of JNK3. Figure 
was modified from Laufer et al.151                                                                                                                                                                                           
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3.2.2.  Exploration of the substitution at the HR I 
The first attempts aimed at increasing the selectivity towards the JNK3 consisted in 
modifying the substitution at the imidazole-C4 position of compound 1. As resulting from 
the well-known binding mode of the class of pyridinylimidazoles, the group in this position 
is accommodated in the HR I, an area of the protein which is crucial in determining the 
inhibitor selectivity. 
Prior to synthesize derivatives carrying different substituents at the imidazole-C4 position, 
a small set of modifications were conducted on the 5-membered core ring (Figure 3.14). 
These changes were aimed at observing the effect of a different substituents arrangement 
around the imidazole ring (such as 1,5- or 4,5-disubstituted imidazoles 21 and 22, 
respectively), along with a change of the core to 2-amino-thiazole (compound 23).  
 
Figure 3.14. Core modifications of the lead compound 17. 
 
Moreover, these structural modifications resulted in an overall simplification of the 
scaffold, alongside with more convenient synthetic procedures.  
The scaffold of compound 21 could be easily obtained through a multistep one-pot reaction 
starting from the 2-bromoisonicotinaldehyde and 4-fluoroaniline, and achieving the ring 
closure through Van Leusen reaction with p-toluenesulfonylisocyanide (Scheme 3.2). The 
same scaffold could be used for the preparation of compound 7 (precursor of probe 11, 
Figure 3.3). 
 
Scheme 3.2. Synthesis route for the preparation of compounds 7 and 21a. 
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Both compounds 22 and 23 could instead be obtained starting from the ethanone 
derivatives 18 (Scheme 3.3). In case of the 4,5-disubstituted imidazole 22 the ethanone was 
reacted in a Riley oxidation giving the corresponding diketone and then cyclized under 
Debus-Radzizewski conditions. The strategy employed for the synthesis of 22 was also 
followed for the preparation of compound 6, precursor of probe 10 (Figure 3.3). Worth to 
mention, the use of a 2-chloro-pyridine derivative instead of the corresponding 2-fluoro 
analog permitted to remarkably increase the yield of both steps, as it significantly reduced 
the substitution of the halogen by a molecule of water. On the other hand, α-bromination 
of ethanone intermediate followed by cyclization with methylthiourea afforded compound 
23.  
 
 
Scheme 3.3. Procedures for the preparation of compounds 6, 22, and 23. 
 
Table 3.5 shows the biological activity of the synthesized compounds on both JNK3 and 
p38α MAPK in comparison with IC50 values of derivative 17.  The different arrangement of 
substituents around the imidazole ring characterizing compound 21 produced a decrease 
in activity of one order of magnitude. Conversely, removal of the S-methyl group or 
replacement of the core with a 2-methylamino-imidazole ring were well tolerated and gave 
rise to compounds potently inhibiting both enzymes. In particular, 4,5-disubstituted 
imidazole 22 displayed extremely similar inhibition values compared to the lead compound 
17, leading to the assumption that the 2-methylsulfanyl substituent doesn’t exert an 
additional influence on the activity. Moreover, likewise its trisubstituted analog 17, 
compound 22 is also characterized by a balanced activity on both kinases (in contrast to 
thiazole derivative 23, showing preference towards the p38α MAPK). These features in 
combination with an easier synthesis route suggested to conduct the following 
modifications on the disubstituted imidazole core rather than on the trisubstituted ring.  
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Table 3.5. Biological activity of compounds derived from modification of the central core 
Cpd 
IC50 ± SD [µM]a 
JNK3 p38α MAPK 
17 0.038 ± 0.002 0.017 ± 0.001 
21 0.276 ± 0.010 0.323 ± 0.014 
22 0.031 ± 0.002 0.021 ± 0.001 
23 0.015 ± 0.003  0.002 ± 0.000 
aValues represent the mean of three experiments 
 
As outlined in Scheme 3.4 the 2-chloro-4-methylpyridine was first deprotonated by sodium 
bis(trimethylsilyl)amide (NaHMDS) and then condensed with the appropriate ester 
obtaining a series of ethanone derivatives carrying different aryl, cycloalkyl, and branched 
alkyl substituents (compounds 34). These intermediates were then converted to the final 
4,5-disubstituted imidazoles using the same procedure reported in Scheme 3.3. 
 
Scheme 3.4. Synthesis of compounds 44-55. 
Such synthetic strategy was unfortunately not applicable to the synthesis of derivatives 
carrying linear alkyl chains (compounds 35), due to the impossibility to condense the 2-
chloro-4-methylpyridine (28) with the corresponding ethyl esters. This could derive from 
the extraction of a proton at the αC of the ester by the deprotonated pyridine, thus 
preventing the nucleophilic attack. The success on the NaHMDS condensation reaction on 
cyclic or branched alkyl moieties, also having a proton in α position to the carbonyl group, 
might be explained by the higher hindrance of their substituents. The synthesis of methyl- 
and ethyl-substituted derivatives 42 and 43, respectively, required therefore a different 
strategy (Scheme 3.5). Ketone derivatives 37 were transformed into the corresponding 
oximes and subsequently tosylated. α-Aminoketones 39 were then obtained by Neber 
rearrangement of tosyloximes 38 followed by hydrolysis of the resulting azirine 
intermediate. Finally, after ring closure with KSCN, the imidazolin-2-thione ring of 
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derivatives 40 was desulfurized in oxidative conditions and the 4-morpholinoaniline 
moiety was successively installed. 
 
 
Scheme 3.5. Synthetic strategy towards 4,5-disubstituted imidazoles 42 and 43 bearing a linear alkyl 
substituent. 
Table 3.6 illustrates the biological activities of compounds featuring different substituents 
at the imidazole-C4(5) position (compounds 42-55) in comparison to the 4-fluorophenyl 
derivative 22. As it can be observed, modification of the substitution pattern around the 
phenyl ring seemed not to influence the activity on the two enzymes, giving rise in most of 
cases to dual JNK3/p38α MAPK inhibitors with IC50 values in the double-digit nM range. 
The lack of selectivity of these derivatives can be explained through the observations of 
previous studies from Scapin and coworkers based on the structural determination of JNK3 
in complex with different inhibitors, including a pyridinylimidazole-based compound.167 
Although the gatekeeper amino acid of JNK3 (Met146) differs from the corresponding 
residue on p38α MAPK (Thr106) the aforementioned studies permitted to observe a shift of 
the Met149 side chain of approximately 3 Å in order to accommodate the aromatic 
substituent on the imidazole core. By affecting the gatekeeper amino acid, this induced fit 
significantly reduces the size difference between the two binding sites, hence not allowing 
the achievement of a selectivity of action. Size increase of the substituent was still well-
tolerated in both cases as exemplified by the high potency of naphthyl derivative 51, 
whereas the substitution with a heteroaromatic 5-membered ring (compound 50) caused a 
loss of activity more prominent on the p38α MAPK.  
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Table 3.6 Structure and biological activity of analogs of compound 22 bearing a different substituent 
at the imidazole-C4 position. 
 
 
Cpd R 
IC50 ± SD [µM]a 
JNK3 p38α MAPK 
22 
 
0.031 ± 0.002 0.021 ± 0.001 
42  0.833 ± 0.139  >10 (41%)
b 
43  1.198 ± 0.193 >10 (34%)
b 
44c 
 
2.833 ± 0.046 ≈10 (50%)b 
45c 
 
>10 (32%)c >10 (41%)b 
46 
 
1.080 ± 0.165 4.023 ± 0.193 
47c 
 
1.757 ± 0.133  2.265 ± 0.177  
48c 
 
2.189 ± 0.136 1.716 ± 0.081 
48c 
 
1.724 ± 0.179  0.726 ± 0.021 
50 
 
0.758 ± 0.049 3.259 ± 0.181 
51 
 
0.031 ± 0.003 0.016 ± 0.003 
52c 
 
0.143 ± 0.012 0.022 ± 0.003  
53c 
 
0.131 ± 0.021 0.061 ± 0.002  
54c 
 
0.060 ± 0.008  0.038 ± 0.002 
55c 
 
0.037 ± 0.003 0.024 ± 0.003 
aIC50 values are the mean of three experiments; bpercent inhibition at indicated 
concentration; ccompounds synthesized by master student Camilla Scarpellini 
under my co-supervision. 
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A different effect could be detected by substituting the 4-fluorophenyl moiety with cyclic 
or branched aliphatic groups. In case of p38α MAPK, the activity decreased along with the 
reduction of the ring size, probably due to the progressive inability to occupy the larger HR 
I of this enzyme. On the other hand, excluding the cyclopropyl derivative 46, the inhibitory 
activity on JNK3 seemed not to be affected by the ring size.  
A possible explanation for this behavior is that the cycloaliphatic moieties are not able to 
induce the shift of the Met146 due to their higher flexibility. As a result, the small size of 
the JNK3 HR I might force the inhibitor to adopt a different conformation wherein the 
imidazole core is flipped of approximately 180° respect to the pyridine ring. Being located 
in the wider phosphate region the cycloalkyl moiety does not contribute to the binding, 
thus explaining the akin inhibitory activity of compounds 47-49. The hypothesis of the 
central core flip can be supported by analogous findings reported by Wytiak and coworkers 
for similar molecules168 and can also be observed by docking these inhibitors in the binding 
site of JNK3, using the crystal structure with PDB entry 3V6S.169 Since the inhibitor 
crystallized in this structure does not target the HR I, the position of the Met146 reflects the 
natural orientation of the JNK3 gatekeeper residue, hence representing the original size of 
this pocket. As exemplified by Figure 3.15, representing the cyclopentyl derivative 48, 
several poses were generated wherein the cycloalkyl substituent pointed away from the HR 
I, thus resulting in a flip of the imidazole ring. It is worth to mention that also poses 
displaying the classical conformation of the imidazole ring were possible, requiring 
however a different orientation of the whole scaffold in order to fit the cyclic substituent in 
the narrower HR I.   
 
 
Figure 3.15. Docking pose of compound 48 (PDB entry: 3V6S). Docking was performed using the 
software Schrödinger Maestro v11.03.016.  
 
Regarding the introduction of branched aliphatic substituents, the isopropyl group 
determined a severe drop of the inhibitory activity on p38α MAPK yet producing μM IC50 
66  3.  RESULTS AND DISCUSSION 
values on JNK3. Substitution with a bulkier tert-butyl moiety was instead not tolerated by 
both enzymes. 
A further decrease in the substituent size, consisting in the introduction of a methyl or an 
ethyl group, resulted in a total loss of inhibitory activity on p38α MAPK (compounds 42 
and 43, respectively). Interestingly, the same substituents managed to conserve the activity 
on the JNK3, with the methyl derivative 42 representing the only example of the series 
reaching an IC50 value in the submicromolar range. This outcome seems to be in line with 
the previous assumptions regarding the effect of cycloalkyl substituents. More closely, the 
methyl group of compound 42 possesses the right size to fit in the narrow HR I of the JNK3 
with the gatekeeper amino acid in its natural conformation, thus not requiring the 180° flip 
of the imidazole ring. Because of the advantageous inhibition profile of compound 42, the 
methyl group at the imidazole-C4(5) position was maintained stable when modifying other 
areas of the scaffold. 
 
3.2.3.  Modifications on the five-membered core  
Once the methyl substituent was selected as a suitable substituent at the imidazole-C4(5) 
position, further structural changes were performed on the central core.  
At a first instance, similar modifications to the ones described in the previous section were 
carried out, aimed at modifying the arrangement of substituents around the imidazole core 
(compounds 56 and 57, Figure 3.16). Alternatively, the imidazole core was replaced by a 2-
aminothiazole ring (compound 58).  
 
 
Figure 3.16. Modifications at the imidazole core maintaining the methyl substituent at the imidazole-
C4(5) position. 
 
For the preparation of the three scaffolds depicted in Figure 3.16 diverse strategies were 
required. In case of inhibitor 56 the procedure reported in Scheme 3.2, based on Van Leusen 
cyclization reaction, was not applicable due to the instability of the corresponding methyl-
imine intermediate. For this reason, the commercially available 5-bromo-N-
methylimidazole (59) was coupled to the (2-chloropyridin-4-yl)boronic acid (60) through a 
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Pd-catalyzed Suzuki-Miyaura coupling reaction (Scheme 3.6). As in the previous examples, 
the 4-morpholinoaniline moiety could be then introduced by nucleophilic aromatic 
substitution.  
 
Scheme 3.6. Synthesis strategy for the preparation of compound 56. 
For the 1,2-disubstituted imidazole scaffold of compound 57 a one-pot reaction starting 
from the 2-chloro-isonicotinonitrile (62) was instead employed, following the procedure 
described by Voss et al.170 (Scheme 3.7).  Finally, the 2-methylaminothiazole core could be 
obtained according to the Hantzsch method, namely by cyclizing an α-halogen carbonyl 
compound with N-methylthiourea. This procedure was analog to the one used for the 
synthesis of the 4-aryl-5-pyridinyl thiazole 23. However, due to the inaccessibility of the 
corresponding ketone derivative (Scheme 3.4), the α-halogenation was conducted on its 
regioisomer 36, thus leading to the 5-methyl-4-pyridinyl thiazole 58. 
 
 
Scheme 3.7. Synthesis route towards 1,2-disubstituted imidazole 57.   
 
Other modifications on the central core consisted instead in altering the substitution pattern 
at the C2 position of the imidazole ring. Firstly, the 2-methylsulfanyl group was 
reintroduced in order to evaluate its possible influence in combination with the 4-methyl 
group (compound 66). Additionally, a 2-amino group was also installed in this position in 
order to observe the effect of an electron donating group (compound 68). From the synthetic 
point of view compound 66 was accessed by alkylating intermediate 40a with methyl iodide 
and proceeding with the nucleophilic aromatic substitution (Scheme 3.8). The same 
procedure allowed to obtain compound 4, the precursor of probe 8 (Figure 3.3). The 2-
aminoimidazole core could instead be obtained by reacting the α-aminoketone 39a with 
cyanamide (Scheme 3.8).  
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Scheme 3.8. Synthesis of derivatives carrying different substituents at the imidazole-C2 position 
The first feature emerging from biological results of compounds 56-58, 66, and 68 (Table 
3.7) is the complete loss of activity on the p38α MAPK which can be mostly attributed to 
the replacement of the 4-fluorophenyl ring with a methyl substituent. 
Table 3.7. Biological activities derivatives resulting from modifications at the central core 
Cpd 
IC50 ± SD [µM]a 
JNK3 p38α MAPK 
56 0.714 ± 0.021 >10 (32%)b 
57 >10 (42%)b >10 (15%)b 
58 2.500 ± 0.092 >10 (9%)b 
66 0.363 ± 0.034 >10 (48%)b 
68 1.395 ± 0.230 >10 (43%)b 
aIC50 values are the mean of three independent 
experiments; bpercent inhibition at 10 μM concentration. 
 
In addition, it can be observed that the replacement of the core to a 1,5-disubstituted 
imidazole (56) was still tolerated whereas the 1,2-disubstitution (57) resulted in a dramatic 
drop in activity. Analogously, a significantly higher IC50 value could be observed when the 
central imidazole core was transformed into a 2-methylaminothiazole (58). The presence of 
the free amino group at the imidazole-C2 position exerted a counterproductive effect on the 
inhibitory activity, producing an IC50 value in the μM range (68). On the other hand, 
reintroduction of the 2-alkylsulfanyl group (66) determined a twofold increase in the 
inhibitory activity. This outcome was surprising since the results displayed in Table 3.5 
hinted a scarce influence of the S-methyl group on the activity of derivatives bearing a 4-
fluorophenyl substituent on the imidazole ring. Conversely, an evident contribution of the 
2-alkylsulfanyl moiety could be observed on the 4-methyl substituted derivatives (a more 
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detailed elucidation of the influence of the S-methyl moiety will be provided in the 
following section). 
After understanding the importance of the S-methyl moiety, a further series of 
pyridinylimidazole derivatives was synthesized wherein an alkyl group was introduced on 
the imidazole N atom while maintaining both the 4-methyl and the 2-alkylsulfanyl 
substituents. Tetrasubstituted imidazoles are present in the core of several p38α MAPK and 
dual JNK3/p38α MAPK potent inhibitors128,151,171 and this strategy was therefore applied to 
the methyl-substituted scaffold as well. When synthesizing tetrasubstituted imidazole 
derivatives as kinase inhibitors a special attention should be given to regioisomery. As it is 
possible to understand from Figure 3.13, the position of the substituted imidazole N atom 
is crucial for the formation of the essential binding interactions. In particular, substitution 
on the imidazole N atom distal to the pyridine ring would hinder the formation of the 
hydrogen bond with Lys93, hence reducing the binding affinity. As a proof of this, the 
tetrasubstituted derivative 70 carrying a methyl group on the imidazole N atom away from 
the pyridine ring was synthesized by reaction of compound 65 with methyl iodide, 
followed by Buchwald-Hartwig amination on intermediate 69. Previous studies have 
demonstrated that the nucleophilic substitution on pyridinylimidazoles tends to occur 
regioselectively on this N atom when a 4-fluorophenyl ring is installed at the imidazole-C4 
position.172 The same reaction carried out on the 4-methyl derivative 65 showed analogous 
regioselectivity, affording compound 69 as the major product as it could be assessed by X-
ray crystallography (Figure 3.17).  
 
Figure 3.17. Synthesis and structure determination of tetrasubstituted derivative 70. 
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The significant drop in inhibitory activity of compound 70 confirmed the previous 
assumptions and prompted the regioselective synthesis of analogs carrying the substitution 
on the imidazole N atom adjacent to the pyridine ring. Such molecules can normally be 
obtained through a route previously reported by Laufer and coworkers entailing the 
cyclization of an α-ketoxime derivative with a trialkyl triazinane in order to introduce the 
substituent in the desired position (Scheme 3.9).173 Nevertheless, the application of this 
strategy starting from compound 37a was only successful in the case of the N-methyl-
substituted imidazole 76, yet being characterized by low yields and long reaction times. For 
this reason, an alternative procedure was developed for the regiospecific preparation of 
tetrasubstituted imidazoles (Scheme 3.9). Such route slightly modifies a strategy previously 
published by Xi et al.174 and is based on the reaction of  the α-aminoketone derivative 39a 
with an opportune alkylisothiocyanate. Diverging from the reported route, the imidazolin-
2-thione intermediates 74 were reacted in a nucleophilic substitution in order to introduce 
the alkyl group on the S atom.   
 
 
Scheme 3.9. Synthetic strategies for the preparation of tetrasubstituted imidazoles. 
 
The route reported in the lower part of Scheme 3.9 was also applied as an alternative and 
versatile strategy for the preparation of previously discovered tetrasubstituted derivatives 
as potent p38α MAPK inhibitors (Publication V).   
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Table 3.8. Biological activity of tetrasubstituted derivatives 76-78. 
 
Cpd R 
IC50 ± SD [µM]a 
JNK3 p38α MAPK 
76  2.514 ± 0.312 > 10 (10%)
b 
77 
 
2.091 ± 0.108 > 10 (21%)b 
78  6.509 ± 1.326 > 10 (40%)
b 
aIC50 values are the mean of three independent experiments; bpercent 
inhibition at 10 μM concentration. 
 
Results displayed in Table 3.8 show that substitution of the imidazole N atom adjacent to 
the pyridine had a detrimental effect on the inhibitory activity. In particular, N-methyl 
derivative 78 showed a drop in inhibitory potency of nearly one order of magnitude 
compared to the N-unsubstituted compound 66. Furthermore, the same compound resulted 
even less active than the supposedly “wrong” regioisomer 70, suggesting that substitution 
in such position might hinder crucial binding interactions. 
After observing the beneficial effect of the 2-alkylsulfanyl group on the imidazole ring, 
analogs of compound 66 bearing an ethyl chain or being unsubstituted at the imidazole-C4 
position were synthesized (compounds 79 and 80, respectively). This detailed evaluation 
was performed in order to estimate the optimal length of the substituent in this position in 
combination with the S-methyl moiety.  Compounds 79 and 80 could be obtained through 
the same procedure used for compound 66 (Schemes 3.5 and 3.8) starting from 1-(2-
chloropyridin-4-yl)butan-1-one and 1-(2-chloropyridin-4-yl)ethan-1-one, respectively. As it 
can be observed from the results in Table 3.9 derivative 66 emerged once more as the best 
inhibitor of the series, thereby confirming the methyl group as the substituent possessing 
the optimal length to address the HR I. 
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Table 3.9. Assessment of the optimal length of the alkyl substituent at the imidazole-C4(5) position.  
 
 
Cpd R 
IC50 ± SD [µM]a 
JNK3 p38α MAPK 
66  0.363 ± 0.034 >10 (48%)
b 
79  1.095 ± 0.064 >10 (38%)
b 
80  0.562 ± 0.021 >10 (43%)
b 
aIC50 values are the mean of three independent experiments; bpercent 
inhibition at 10 μM concentration. 
 
 
3.2.4.  Evaluation of the binding mode of compounds 42 and 66 
In order to understand the influence of the 2-alkysulfanyl moiety in derivative 66 and to 
explain its significantly higher inhibitory activity in comparison to the 2-unsubstituted 
analog 42, the structure of JNK3 in complex with the two derivatives was determined by X-
ray crystallography. A preliminary assumption consisted in the capability of the S-methyl 
group of inhibitor 66 to prevent the potential 180° flip of the imidazole ring which can 
instead occur in derivative 42, as already hypothesized for aforementioned compounds 
(Section 3.2.2. and Figure 3.15). This conformational change might be responsible for the 
twofold drop in inhibitory activity of compound 42. Nevertheless, as noticeable from the 
two crystal structures depicted in Figure 3.18, both inhibitors assumed the “classical” 
conformation with the 4-methyl substituent pointing towards the HR I of the enzyme, and 
the imidazole N atom interacting with the conserved Lys93 via a double water-mediated 
hydrogen bond. These findings seem therefore to rule out the hypothesis of the imidazole 
flip.  
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Figure 3.18. Crystal structures of inhibitors 42 (A, PDB entry: 6EMH) and 66 (B, PDB entry: 6EKD) 
soaked in JNK3. Only the JNK3 active site is displayed. The protein backbone is displayed in gray. 
The compounds and interacting amino acids are highlighted as sticks. Active site residues with 
common orientations and interactions are shown in light blue, while the residues that differ between 
both complexes are highlighted in the same color as the respective inhibitor. Side chains for which 
multiple orientations are observed (Asn194 in complex with 42 and Asn152 in complex with 66) are 
shown in both orientations. Water molecules are represented as red spheres and hydrogen bonds 
are shown as black dashed lines. 
 
General observations which can be done for both inhibitors are the bidentate hydrogen 
bond interaction with the Met149 and the formation of a water-mediated hydrogen bond 
between the imidazole N atom adjacent to the pyridine ring and the Asn152. The latter 
finding might explain the detrimental effect of alkyl substituents in this region (Table 3.8) 
(a more detailed description of the binding mode of the two inhibitors is presented in 
Publication VII). A major feature distinguishing the two crystal structures is the position 
of the conserved Gly-rich loop (see Section 1.1.1). In the case of the unsubstituted derivative 
42 this region is lacking electron density due to high flexibility. Conversely, inhibitor 66 
seems to stabilize this segment thanks to both hydrophobic and polar interactions, 
positioning it in a downward conformation. A closer analysis of this behavior based on the 
superposition of different crystal structures (Figure 3.19) revealed that inhibitor 66 induces 
a collapse of the Gly-rich loop akin to the one visible in the JNK3-AMP-PCP complex (PDB 
entry: 6EQ9), thus determining a compression of the ATP binding site. This effect which is 
driven by the S-methyl moiety seems therefore to be the responsible for the higher 
inhibitory potency of compound 66 in comparison with derivative 42. 
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Figure 3.19. Comparison of gatekeeper Met146 orientation and the Gly-rich loop positioning upon 
JNK3 inhibitor binding with other ligand-bound JNK3 structures. Overlay of the JNK3-66 complex 
structure (light green), the JNK3-42 complex structure (light red), the AMP-PCP bound JNK3 
structure (light orange), and the 1PMN structure reported by Scapin, et al.167 (blue). The 
superposition was performed using the “align” function in PyMOL. The side chain of the gatekeeper 
Met146 and the Gly-rich loop are highlighted. Only compounds 42 and 66 are shown for the sake of 
clarity. 
 
Other considerations on the inhibitors binding mode regard the positioning of the Met146 
side chain, representing the gatekeeper of the enzyme. As expected, in both complexes with 
the 4-methyl substituted inhibitors 42 and 66 the gatekeeper is in a “natural” conformation, 
resembling the one of the JNK3-AMP-PCP complex. On the other side, as already 
mentioned in section 3.2.2., aryl substituents in this position can induce a shift in of the 
Met146 side chain, thus increasing the size of this hydrophobic pocket, as also visible in 
Figure 3.19 for the 1PMN crystal structure (blue). By binding to the enzyme with the 
gatekeeper in its natural conformation 4-methyl substituted derivatives present the optimal 
length to occupy the narrow HR I of the JNK3 while being too small to interact with the 
wider pocket in p38α MAPK. This explanation might therefore provide a rationale for the 
high selectivity of compounds 42 and 66 towards the JNK3.  
 
3.2.5.  Modification of the substituent at the HR II 
The last series of modifications consisted in the replacement of the 4-morpholinoaniline 
substituent of compound 66 with different aliphatic and aromatic substituents. Such 
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derivatives could be easily synthesized by nucleophilic aromatic substitution starting from 
intermediate 65 (Scheme 3.8). 
The first attempt consisted in introducing moieties which have been previously reported in 
potent pyridinylimidazole-base inhibitors of the p38α MAPK. In detail, the 3-methylbut-2-
ylamine and the 1-phenylethyl-1-amine, which can be found in the structure of the LN950143 
and ML3403,151 respectively, were installed at this position giving rise to derivatives 81 and 
82, respectively (Figure 3.20).  
 
 
Figure 3.20. Design and biological activities of compounds 81 and 82. 
The purpose of this strategy was to increase the potency on the JNK3 by inserting groups 
which resulted beneficial for the closely-related p38α MAPK while maintaining the 
selectivity of action provided by the methyl substituent on the imidazole core. 
Nevertheless, results displayed in Figure 3.20 revealed that this approach is 
counterproductive, as besides a dramatic loss in activity on JNK3 for both compounds 81 
and 82, the substituent of compound 82 could even restore the inhibitory activity on the 
p38α MAPK. The effect of the two branched alkyl/arylalkyl substituents of p38α MAPK 
standard inhibitors LN950 and ML3403 was further evaluated on different cores and 
compared with the corresponding derivatives bearing the aromatic 4-morpholinoaniline/p-
phenylendiamine groups (Figure 3.21). In accordance with the results observed for 
compounds 81 and 82, the 3-methylbut-2-ylamine and the 1-phenylethyl-1-amine were 
scarcely tolerated at the pyridine-C2 position also when combined with other cores. This 
demonstrates that, despite their high similarity, the JNK3 and the p38α MAPK present 
different requirements when targeting this area of the protein. 
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Figure 3.21. Effect of substituents at the pyridine-C2 position in combination with different cores; 
aEitel, M.; Koch, P., unpublished results; bcompound reported in the diploma thesis from Philipp 
Krause; cEl-Gokha, A.; Koch, P.; unpublished results; 
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In addition, the substitution at the pyridine-C2 position was further explored through the 
insertion of different cycloalkyl moieties (Figure 3.22). Despite not producing any 
improvement on JNK3 inhibition, cycloaliphatic substituents showed an increase in activity 
alongside with the size of the cycle thus underlining the importance of hydrophobic 
interactions in this area.  
 
 
 
Figure 3.22. Structure and biological activity of derivatives bearing different substituents at the 
pyridine-C2-N position; all compounds showed IC50(p38α MAPK) > 10 μM. 
 
As noticeable in the crystal structure of derivative 66 in complex with JNK3 (Figure 3.18), a 
potential chance to increase the inhibitory activity is represented by the targeting of Gln155, 
a residue located in the HR II of the enzyme and only 4 Å away from the N atom of the 
morpholine moiety. In order to achieve a sufficient flexibility to reach the Gln155, a trans-
4-aminocyclohexanol and a trans-cyclohexane-1,4-diamine groups were installed at the 
pyridine-C2 position (compounds 99 and 100, respectively). The former group was 
previously reported in potent p38α MAPK inhibitors151 and is present in the JNK clinical 
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candidate CC-930/Tanzisertib (Table 1.1) wherein its capability to target the Gln155 was 
confirmed by crystal structure (Figure 3.23). Due to the similarity between Tanzisertib and 
compound 99 at the hinge binding motif, the introduction of the same substituent was 
supposed to enable the formation of a hydrogen bond with the side chain of Gln155, as also 
predicted by docking studies (Figure 3.23).  
 
 
Figure 3.23. Possible analogies in the binding mode of CC-930/Tanzisertib and compound 99; A) 
structural similarity between Tanzisertib and compound 99; B) comparison between crystal 
structure of Tanzisertib (green) in complex with JNK3 (PDB entry: 3TTI) and compound 99 (cyan) 
docked in the same enzyme (PDB entry: 6EKD); analogously to the Tanzisertib, compound 99 shows 
the possibility to target the Gln155 through the formation of a hydrogen bond. 
 
Nevertheless, lower inhibitory activity of compound 99 in comparison with derivative 66 
hints that an additional interaction might not be formed by the new substituent. 
Alternatively, the decreased inhibition might suggest once more the necessity of a phenyl 
ring in this region, rather than alkyl moieties. In order to increase the length of the 
substituent and improve its capability to target the side chain of Gln155, a series of amides 
was prepared starting both from compound 100 as well as from its aromatic analog 101 
(Figure 3.22). In this way it would be possible to introduce a group able to act as both 
hydrogen donor and acceptor and to seek for additional interactions within the HR II. 
Unfortunately, none of the derivatives of this series were able to overcome the inhibitory 
activity of compound 66, resulting in most cases even weaker than their amine precursors. 
An overall analysis of the biological activity within this series permits once again to assess 
the better suitability of the aromatic derivatives over their cycloaliphatic counterparts; 
furthermore, increasing the size of the substituent at this position was not beneficial, as the 
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small acetamido derivatives 102 and 106 represented the most active compounds of the 
group. 
 
3.2.6.  Further characterization of compound 66 
Since compound 66 represented the most potent and selective derivative synthesized in this 
work, a further characterization was carried out. At a first instance the intra-JNK selectivity 
was evaluated in order to understand whether such scaffold might possess selectivity 
towards one of the members of the JNK family. Results displayed in Table 3.10 only 
highlighted a slight selectivity of derivative 66 over the JNK2 isoform, although the three 
kinases showed similar IC50 values. 
Table 3.10. Inhibitory activity of compound 66 on the three JNK isoforms 
IC50 [nM] 
JNK1 JNK2 JNK3 
119 468 184 
Compounds were tested by Reaction Biology corporation 
(Malvern, PA, USA) using a radiometric assay. 
 
In order to spot potential liabilities to be addressed in a following optimization process 
compound 66 was also evaluated for its metabolic stability as well for non-specific 
interactions with potential off-targets.  
Initially, the metabolic stability was evaluated in in vitro experiments performed by 
incubating the compound with human liver microsomes (HLM). A major drawback of 2-
alkylsulfanyl derivatives is represented by their intense metabolization, mostly consisting 
in the oxidation of the thioether group to the corresponding sulfoxide moiety.175  
 
 
Figure 3.23. Plotted results of metabolic stability assays on HLM. 
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Experiments performed on compound 66 revealed instead a relative stability, leaving 
approximately 80% of the unmodified product after 4 h incubation (Figure 3.24). 
Compound 66 was additionally tested for its capability to interact with cytochrome P450 
(CYP450) enzymes as well with human ether-à-go-go related gene (hERG) channels, both 
representing common non-specific off-targets of different drugs. In particular, CYP450 
inhibition constitutes a prevalent liability of pyridinylimidazole scaffolds, mainly 
depending on their aptitude to coordinate the prosthetic haem iron of these enzymes.165,176  
 
Table 3.11. inhibition of hERG channels and CYP450 enzymes by compound 66 
hERG inhibition 
[% inhibition at 10 μM] 
CYP450 inhibiton [% inhibition at 10 μM] 
1A9 2C9 2C19 2D6 3A4 
38.8 51.5 53.9 35.6 19.0 75.1 
 
 
Data presented in Table 3.11 seem to display a reduced inhibition of four out of five tested 
isoenzymes. Nevertheless, the elevated inhibition of the most prominent isoform 3A4 
represents a non-negligible shortcoming which would need to be resolved in following 
optimization strategies. On the other side, compound 66 displayed low interaction with the 
hERG channels, with less than 40% inhibition at 10 μM. 
 
3.2.7. Application of a covalent inhibition strategy on compound 66 
Due to the high selectivity of derivative 66 over the p38α MAPK, the 4-methyl-substituted 
imidazole scaffold was selected as a starting point for the synthesis of irreversible 
inhibitors. As already mentioned in section 1.1.2. such inhibitors are composed by a core 
structure binding reversibly to the ATP cleft and by a mildly electrophilic moiety targeting 
a non-conserved Cys residue in the proximity of the binding site. In particular, as noticeable 
from the sequence alignment illustrated in Figure 1.7, a Cys residue located in the JNK3 HR 
II (Cys154, JNK3 numbering) is not conserved in the binding site of p38α MAPK thus 
resulting suitable to be addressed by the electrophilic warhead. A similar strategy was 
previously adopted by Zhang and coworkers on a 2-amino-4-pyridinylpyrimidine scaffold 
giving rise to the potent high quality kinase probe JNK-IN-8169 (Figure 3.24). In such 
approach an acrylamide-based warhead was linked to the main scaffold through a spacer 
represented by two aromatic rings connected by an amide bond.  
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Figure 3.24. Covalent inhibition strategy on the pyridinylimidazole scaffold based on high quality 
probe JNK-IN-8. 
 
Due to the resemblance between the binding mode of JNK-IN-8 and compound 66, mainly 
centered on the bidentate hydrogen bond with the backbone of Met149, an analogous 
combination of spacer/warhead was installed on the pyridinylimidazole scaffold of the 
latter inhibitor. Since the linker needs to comprise the optimal length in order to position 
the reactive moiety in proximity of the targeted Cys residue, both the meta- and para-
substituted derivatives were synthesized (compounds 110 and 111, respectively). 
 
Table 3.12. Structure and biological activities of compounds 110-112. 
 
Cpd R 
IC50 ± SD [μM]a  
JNK3b p38α MAPKc 
110d meta 
 
0.002 ± 0.0003 1.952 ± 0.062 
110d para 
 
0.200 ± 0.021 5.920 ± 0.107 
112 meta 
 
0.253 ± 0.015 >10 
aIC50 values are the mean of three independent experiments; 
bincubation time 50 min; cincubation time 60 min; dcompound 
synthesized by Dr. Ahmed El-Gokha. 
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Results displayed in Table 3.12 demonstrate the success of the covalent inhibition strategy 
transferred to the pyridinylimidazole scaffold. More closely, the insertion of the covalent 
warhead at the meta position of the phenyl ring (compound 110) permitted to reach an IC50 
value in the low single digit nM range while maintaining the selectivity over the p38α 
MAPK. Such inhibitory activity was more than 100-fold higher than the one exhibited by 
the para-substituted derivative 111, proving the latter substitution pattern not to be optimal 
to target the Cys154. In addition, the significantly higher IC50 value of compound 112, 
representing the saturated analog of inhibitor 110, permitted to attribute the high inhibitory 
activity of the latter to the formation of the covalent bond. A further demonstration of the 
irreversible targeting of Cys154 could be provided by mass shifts experiments performed 
by liquid chromatography-mass spectroscopy (LC-MS) analysis of the JNK3 after 
incubation with the inhibitor. Prior to the measurement, a declustering potential was 
applied to the sample in order to disrupt weak electrostatic interactions. In case of 
compound 110 a mass shift corresponding to the molecular weight of the inhibitor could be 
detected. Conversely, the same result was not obtained when performing the LC-MS 
experiment on the saturated analog 112, once more confirming the covalent mechanism of 
action of derivative 110. Additionally, the Cys154 was identified as the amino acid targeted 
by the irreversible inhibitor, since incubation of compound 110 with a JNK3 mutant 
wherein Cys154 was replaced by Ala did not result in an increase in molecular weight. 
 
 
 
 
 
 
 
 
  
Experimental section 
The following section includes the detailed procedures for the preparation of those 
compounds presented in the thesis work which were not included in any of the accepted 
publications or in the submitted manuscript. 
 
General 
All reagents and solvents were of commercial quality and utilized without further 
purification. Yields were calculated on the pure product and were not optimized. Thin layer 
chromatography (TLC) reaction controls were performed for all reactions using fluorescent 
silica gel 60 F254 plates (Merck) and visualized under natural light and UV illumination at 
254 and 366 nm. The purity of all tested compounds are > 95% as determined via reverse 
phase high performance liquid chromatography (HPLC) using one of the 2 following 
methods. For Method A the instrument used was a Hewlett Packard HP 1090 Series II LC 
equipped with a UV diode array detector (DAD, detection at 230 nm and 254 nm). The 
chromatographic separation was performed on a Phenomenex Luna 5u C8 column (150 mm 
x 4.6 mm, 5 μm) at 35 °C oven temperature. The injection volume was 5 μL and the flow 1.5 
mL / min using the following gradient: 0.01 M KH2PO4, pH 2.3 (solvent A), MeOH (solvent 
B), 40% B to 85% B in 8 min; 85% B for 5 min; 85% to 40% B in 1 min; 40% B for 2 min; stop 
time 16 min. Alternatively, for Method B, Agilent 1100 Series HPLC system was used, 
equipped with a UV DAD (detection at 218 nM, 254 nm and 280 nm). The chromatographic 
separation was performed on a XBridgeTM C18 column (150 mm x 4.6 mm, 5 µm) at 30 °C 
oven temperature. The injection volume was 10 μL and the flow 1.5 mL / min using the 
following gradient: 0.01 M KH2PO4, pH 2.3 (solvent A), MeOH (solvent B), 45% B to 85% B 
in 9 min; 85% B for 6 min; stop time 16 min. Column chromatography was performed on 
Davisil LC60A 20 - 45 µm silica from Grace Davison and Geduran Si60 63-200 µm silica 
from Merck for the pre-column using an Interchim PuriFlash 430 automated flash 
chromatography system. Nuclear magnetic resonance (NMR) spectra were measured on a 
Bruker ARX NMR spectrometer at 250 MHz or on a Bruker Avance III HD NMR 
spectrometer at 300 MHz in the Organic Chemistry Institute, Eberhard Karls Universität 
Tübingen or on a Bruker Avance NMR spectrometer at 400 MHz in the Institute of 
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Pharmaceutical Sciences, Eberhard Karls Universität Tübingen. Chemical shifts are 
reported in parts per million (ppm) relative to tetramethylsilane. All spectra were calibrated 
against the (residual proton) peak of the deuterated solvent used. Mass spectra were 
performed on an Advion Expression S electrospray ionization mass spectrometer (ESI-MS) 
with TLC interface in the Institute of Pharmaceutical Sciences, Eberhard Karls Universität 
Tübingen.  
 
Detailed procedures  
N1-(4-(2-(Methylthio)-1H-imidazol-5-yl)pyridin-2-yl)benzene-1,4-diamine (5) 
In a pressure vial 2-chloro-4-(2-(methylthio)-1H-imidazol-5-
yl)pyridine (248 mg, 1.1 mmol, for the synthesis of 2-chloro-4-(2-
(methylthio)-1H-imidazol-5-yl)pyridine see Publication VII) and p-
phenylendiamine (154 mg, 1.5 mmol) were dissolved in n-butanol and 
after that 1.25 M HCl in EtOH (880 μL, 1.1 mmol) was added in one 
portion. The vial was tightly closed and the reaction was heated at 180 °C and stirred for 12 
h. The solvent was evaporated at reduced pressure and the residue was purified twice by 
flash column chromatography (SiO2, DCM/EtOH gradient elution from 97:03 to 50:50) and 
(SiO2, DCM/EtOH 85:15) obtaining 165 mg of the desired product (50% yield); 1H NMR 
(400 MHz, DMSO-d6) δ 2.58 (s, 3H), 4.75 (br. s, 2H), 6.55 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 4.5 
Hz, 1H), 7.08 (br. s, 1H), 7.25 (d, J = 7.8 Hz, 2H), 7.72 (br. s, 1H), 7.97 (d, J = 5.1 Hz, 1H), 8.43 
(s, 1H), 12.46 (br. s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 15.3, 103.2, 108.9, 114.3, 115.1, 
116.7, 121.5, 131.0, 139.4, 142.0, 143.2, 147.5, 157.6; ESI-MS: (m/z) 296.2 [M-H]-, 298.2 [M+H]+; 
HPLC (B): tr = 1.860 min.  
 
N1-(4-(1-(4-Fluorophenyl)-1H-imidazol-5-yl)pyridin-2-yl)benzene-1,4-diamine (7) 
 In a pressure vial 2-bromo-4-(1-(4-fluorophenyl)-1H-imidazol-5-
yl)pyridine (27, 300 mg, 0.94 mmol, for the synthesis of compound 27  see 
Publication VII) and p-phenylendiamine (509 mg, 4.71 mmol) were 
suspended in n-butanol (3 mL) and after that 1.25 M HCl in EtOH was 
added (752 μL, 0.94 mmol). After tightly closing the vial the reaction was 
heated at 180 °C and stirred overnight (18 h); After evaporating the solvent 
at reduced pressure the residue was purified by flash column 
chromatography (SiO2, DCM/EtOH gradient elution from 100:0 to 95:05) giving 260 mg of 
the desired product (80% yield); 1H NMR (250 MHz, DMSO-d6) δ 4.78 (br. s, 2H), 6.27 (s, 
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1H), 6.37 (dd, J = 5.4, 1.2 Hz, 1H), 6.45 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 7.31 - 7.48 
(m, 5H), 7.93 (d, J = 5.1 Hz, 1H), 7.96 (d, J = 1.7 Hz, 1H), 8.35 (s, 1H); 13C NMR (101 MHz, 
DMSO-d6) δ 105.4, 111.2, 114.2, 116.5 (d, J = 21.9 Hz), 122.0, 127.8 (d, J = 8.8 Hz), 129.7, 129.8, 
130.7, 132.5, 137.2, 140.7, 143.9, 148.0, 157.3, 161.5 (d, J = 245.9 Hz); ESI-MS: (m/z) 344.2 [M-
H]-, 346.1 [M+H]+; HPLC (A): tr = 2.487 min.  
 
1-(3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-3-(4-((4-(4-methyl-
2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)phenyl)thiourea (8) 
Compound 4 (100 mg, 0.32 mmol, for the synthesis of 
compound 4 see Publication IV) was dissolved in 
aceton (≈ 20 mL) and after that fluorescein-
isothiocyanate isomer 5’(6’) (188 mg, 0.48 mmol) was 
added and the mixture was stirred for 24 h protected 
from light. After removing the solvent at reduced 
pressure the residue was purified twice by flash column 
chromatography (SiO2, DCM/MeOH gradient elution from 95:05 to 90:10) and (SiO2, 
DCM/EtOH gradient elution from 95:05 to 50:50) obtaining 101 mg of the desired product 
(45% yield);   1H NMR (250 MHz, DMSO-d6) δ 2.43 (s, 3H), 2.56 (s, 3H), 6.55 - 6.74 (m, 6H), 
7.00 (d, J = 4.6 Hz, 1H), 7.12 - 7.26 (m, 2H), 7.38 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 8.5 Hz, 2H), 
7.91 (d, J = 8.1 Hz, 1H), 8.09 (d, J = 5.4 Hz, 1H), 8.39 (s, 1H), 9.14 (br. s., 1H), 10.25 (br. s., 2H), 
10.49 (br. s., 1H), 10.86 (br. s., 1H), 12.41 (br. s., 1H); 13C NMR (75 MHz, DMSO-d6) δ 11.5, 
15.5, 52.1, 102.3, 106.2, 109.8, 111.3, 112.9, 116.9, 117.7, 124.0, 124.6, 127.4, 129.1, 129.6, 131.4, 
134.0, 135.6, 139.2, 139.4, 141.7, 143.2, 147.2, 152.0, 156.3, 160.0, 168.7, 179.3; ESI-MS: (m/z) 
699.3 [M-H]-; HPLC (B): tr = 7.514 min.  
 
1-(3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-3-(4-((4-(2-
(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)phenyl)thiourea (9) 
The title compound was synthesized following the 
same procedure as compound 8 starting from 
compound 5 (60 mg, 0.20 mmol) and fluorescein-
isothiocyanate isomer 5’(6’) (118 mg, 0.30 mmol) (8 h). 
The crude product was purified by flash column 
chromatography (DCM/EtOH gradient elution from 
95:05 to 70:30) obtaining 102 mg of the desired product; 
1H NMR (250 MHz, DMSO-d6) δ 2.59 (s, 3H), 6.55 – 6.73 (m, 6H), 7.04 (d, J = 5.1 Hz, 1H), 
7.19 (d, J = 8.3 Hz, 1H), 7.27 (br. s, 1H), 7.34 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.7 Hz, 2H), 7.80 
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(br. s, 1H), 7.86 (dd, J = 8.1, 1.8 Hz, 1H), 8.07 (d, J = 5.3 Hz, 1H), 8.29 (d, J = 1.4 Hz, 1H), 9.13 
(s, 1H), 10.00 – 10.45 (m, 4H), 12.51 (br. s, 1H);  13C NMR (75 MHz, DMSO-d6) δ 15.2, 48.6, 
102.3, 105.0, 109.8, 110.3, 112.8, 117.0, 117.3, 117.9, 124.0, 124.8, 126.6, 129.1, 130.0, 131.3, 
139.1, 139.4, 141.6, 142.2, 147.3, 152.0, 156.5, 159.8, 168.6, 179.4; ESI-MS: (m/z) 685.3 [M-H]-; 
HPLC (B): tr = 7.292 min.  
 
4-(1-(4-Fluorophenyl)-1H-imidazol-5-yl)-N-(3-methylbutan-2-yl)pyridin-2-amine (85) 
In a pressure vial 2-bromo-4-(1-(4-fluorophenyl)-1H-imidazol-5-
yl)pyridine (27, 100 mg, 0.31 mmol, for the synthesis of compound 27  see 
Publication VII) was suspended in 3-methylbutan-2-amine (700 μL, 6.2 
mmol) and after closing the vial the reaction mixture was heated at 180 °C 
for 96 h; H2O was added and the aqueous layer was then exctracted three 
times with EtOAc. The combined organic layers were then washed with 
H2O and NaCl saturated solution, dried over anhydrous Na2SO4 and 
concentrated at reduced pressure. The residue was then purified by flash column 
chromatography (SiO2, DCM/EtOH gradient elution from 100:0 to 95:05) giving 42 mg of 
the desired product (42% yield); 1H NMR (250 MHz, DMSO-d6) δ 0.81 (t, J = 6.3 Hz, 6H), 
0.95 (d, J = 6.6 Hz, 3H), 1.56 - 1.75 (m, 1H), 3.56 - 3.64 (m, 1H, partially overlapping with the 
H2O signal), 6.11 (d, J = 5.1 Hz, 1H), 6.18 (s, 1H), 6.26 (d, J = 8.3 Hz, 1H), 7.25 - 7.48 (m, 5H), 
7.79 (d, J = 5.1 Hz, 1H), 7.95 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 16.4, 17.7, 19.2, 31.8, 
50.7, 105.3, 109.5, 116.4 (d, J = 22.7 Hz), 127.9 (d, J = 8.8 Hz), 129.4, 131.0, 132.6, 136.8, 140.5, 
147.8, 158.7, 161.5 (d, J = 245.9 Hz); ESI-MS: (m/z) 323.2 [M-H]- , 325.4 [M+H]+; HPLC (A): tr 
= 4.975 min.  
 
N1-(4-(1-Methyl-1H-imidazol-2-yl)pyridin-2-yl)benzene-1,4-diamine (87) 
In a pressure vial 2-chloro-4-(1-methyl-1H-imidazol-2-yl)pyridine (64, 
200 mg, 1.0 mmol, for the synthesis of compound 64  see Publication VII) 
and p-phenylendiamine (168 mg, 1.5 mmol) were suspended in n-
butanol and then 1.25 M HCl in EtOH (826 μL, 1.0 mmol) was added and 
the close vial was heated at 180 °C and stirred for 17 h. After evaporating 
the solvent at reduced pressure the crude residue was purified by flash 
column chromatography (SiO2, DCM/EtOH gradient elution from 100:0 to 80:20) obtaining 
66 mg of the desired product (24% yield); 1H NMR (400 MHz, DMSO-d6) δ 3.79 (s, 3H), 4.81 
(br. s, 2H), 6.54 (d, J = 8.3 Hz, 2H), 6.91 (d, J = 4.5 Hz, 1H), 7.00 (s, 1H), 6.97 (s, 1H), 7.22 (d, 
J = 8.3 Hz, 2H), 7.29 (s, 1H), 8.09 (d, J = 5.3 Hz, 1H), 8.56 (s, 1H)13C NMR (101 MHz, DMSO-
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d6) δ 34.6, 107.1, 111.3, 114.6, 121.6, 124.4, 127.8, 130.8, 138.3, 142.8, 144.5, 147.6, 157.3; FAB-
MS (m/z) 266.3 [M+H]+; HPLC (B): tr = 1.067 min.  
 
4-(1-Methyl-1H-imidazol-2-yl)-N-(3-methylbutan-2-yl)pyridin-2-amine (88) 
The title compound was synthesized following the same procedure used 
for compound 85 starting from 2-chloro-4-(1-methyl-1H-imidazol-2-
yl)pyridine (64, 65 mg, 0.33 mmol, for the synthesis of compound 64  see 
Publication VII) and 3-methylbutan-2-amine (773 μL, 6.71 mmol) (48 h). 
After the work up the residue was purified by flash column 
chromatography (SiO2, DCM/EtOH 97:03) giving 40 mg of the desired 
product (48% yield); 1H NMR (400 MHz, DMSO-d6) δ 0.91 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 6.8 
Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 1.72 - 1.87 (m, 1H), 3.77 (s, 3H), 3.82 - 3.93 (m, 1H), 6.41 (d, 
J = 8.1 Hz, 1H), 6.73 (d, J = 5.3 Hz, 1H), 6.81 (s, 1H), 6.98 (s, 1H), 7.26 (s, 1H), 7.99 (d, J = 5.3 
Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 16.7, 18.0, 19.2, 32.0, 34.5, 50.4, 106.8, 109.8, 124.1, 
127.8, 138.1, 144.9, 147.7, 158.9; FAB-MS (m/z) 245.3 [M+H]+; HPLC (A): tr = 2.534 min.  
 
4-(1-Methyl-1H-imidazol-2-yl)-N-(1-phenylethyl)pyridin-2-amine (89) 
The title compound was synthesized following the same procedure used 
for compound 85 starting from 2-chloro-4-(1-methyl-1H-imidazol-2-
yl)pyridine (64, 200 mg, 1.0 mmol, for the synthesis of compound 64  see 
Publication VII) and 1-phenylethan-1-amine (2.63 mL, 20.65 mmol) (72 h). 
After the work up the residue was purified by flash column 
chromatography (SiO2, DCM/EtOH 97:03) giving 130 mg of the desired 
product (45% yield); 1H NMR (400 MHz, DMSO-d6) δ 1.45 (d, J = 6.8 Hz, 3H), 3.70 (s, 3H), 
4.96 - 5.12 (m, 1H), 6.68 - 6.85 (m, 2H), 6.99 (s, 1H), 7.08 - 7.22 (m, 2H), 7.23 - 7.34 (m, 3H), 
7.35 - 7.45 (m, 2H), 7.91 - 8.04 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 23.6, 34.4, 49.8, 
106.5, 110.5, 124.2, 125.9, 126.3, 127.8, 128.1, 138.2, 144.6, 145.9, 147.8, 158.3; FAB-MS (m/z) 
279.3 [M+H]+; HPLC (A): tr = 3.293 min.  
 
4-(4-(4-Fluorophenyl)-1H-imidazol-5-yl)-N-(3-methylbutan-2-yl)pyridin-2-amine (90) 
The title compound was synthesized following the same procedure used for compound 85 
starting from 2-fluoro-4-(4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine (70 mg, 0.27 mmol, 
for the synthesis of 2-fluoro-4-(4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine see 
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Publication I) and 3-methylbutan-2-amine (626 μL, 5.44 mmol) (48 h). 
After the work up, the residue was purified by flash column 
chromatography (SiO2, DCM/EtOH gradient elution from 95:05 to 85:15) 
giving 47 mg of the desired product (40% yield); 1H NMR (250 MHz, 
DMSO-d6) δ 0.89 - 1.14 (m, 6H), 1.20 (d, J = 6.6 Hz, 3H), 1.80 - 2.03 (m, 1H), 
2.70 (s, 3H), 3.88 (d, J = 6.3 Hz, 1H), 6.48 (br. s, 1H), 6.61 (d, J = 5.1 Hz, 1H), 
6.78 (br. s, 1H), 7.29 - 7.54 (m, 2H), 7.61 - 7.79 (m, 2H), 7.91 - 8.13 (m, 2H), 
12.77 (br. s, 1H); ESI-MS: (m/z) 323.3 [M-H]- , 325.3 [M+H]+; HPLC (A): tr = 
3.376 min.  
 
N1-(4-(5-Methyl-2-(methylamino)thiazol-4-yl)pyridin-2-yl)benzene-1,4-diamine (93) 
The title compound was synthesized following the same procedure 
of compound 7 starting from 4-(2-chloropyridin-4-yl)-N,5-
dimethylthiazol-2-amine (200 mg, 0.83 mmol, synthesis of 4-(2-
chloropyridin-4-yl)-N,5-dimethylthiazol-2-amine can be found in 
Publication VII), p-phenylendiamine (451 mg, 4.17 mmol), and 1.25 
M HCl in EtOH (664 μL, 0.83 mmol) (18 h). After evaporating the 
solvent at reduced pressure the residue was purified by flash 
column chromatography (SiO2, DCM/EtOH gradient elution from 100:0 to 90:10) giving 95 
mg of the desired product (27% yield); 1H NMR (250 MHz, DMSO-d6) δ 2.37 (s, 3H), 2.80 (d, 
J = 4.6 Hz, 3H), 4.73 (br. s, 2H), 6.53 (d, J = 8.8 Hz, 2H), 6.80 (dd, J = 5.4, 1.2 Hz, 1H), 6.90 (s, 
1H), 7.22 (d, J = 8.5 Hz, 2H), 7.33 (q, J = 4.7 Hz, 1H), 8.02 (d, J = 5.4 Hz, 1H), 8.43 (s, 1H); 13C 
NMR (101 MHz, DMSO-d6) δ 12.2, 30.7, 107.1, 112.0, 114.2, 117.1, 121.5, 130.8, 143.2, 143.4, 
143.5, 147.3, 157.4, 165.4; ESI-MS: (m/z) 310.2 [M-H]- , 312.2 [M+H]+; HPLC (A): tr = 2.625 
min.  
 
N,5-Dimethyl-4-(2-((3-methylbutan-2-yl)amino)pyridin-4-yl)thiazol-2-amine (94) 
The title compound was synthesized following the same procedure 
used for compound 85 starting from 4-(2-chloropyridin-4-yl)-N,5-
dimethylthiazol-2-amine (135 mg, 0.56 mmol, the synthesis of 4-(2-
chloropyridin-4-yl)-N,5-dimethylthiazol-2-amine can be found in 
Publication I) and 3-methylbutan-2-amine (1.29 mL, 11.3 mmol) (42 
h). After the work up the residue was purified by flash column 
chromatography (SiO2, DCM/EtOH gradient elution from 100:0 to 90:10) giving 47 mg of 
the desired product (30% yield); 1H NMR (250 MHz, DMSO-d6) δ 0.91 - 1.04 (m, 6H), 1.12 
(d, J = 6.6 Hz, 3H), 1.78 - 1.96 (m, 1H), 2.44 (s, 3H), 2.89 (d, J = 4.9 Hz, 3H), 3.82 - 4.03 (m, 
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1H), 6.38 (d, J = 8.3 Hz, 1H), 6.71 (dd, J = 5.4, 1.2 Hz, 1H), 6.81 (br. s, 1H), 7.37 (q, J = 4.6 Hz, 
1H), 7.99 (d, J = 5.4 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 12.2, 16.7, 17.9, 19.2, 30.6, 32.0, 
50.3, 107.0, 110.4, 116.6, 142.8, 143.8, 147.1, 158.9, 165.2; ESI-MS: (m/z) 289.2 [M-H]- , 291.2 
[M+H]+; HPLC (B): tr = 4.423 min.  
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